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Background. Clinicians are divided on dosing recommendations when a dose is 
delayed or missed. For a neuropsychiatric agent like valproic acid (VPA), rational dosing 
recommendations are of particular importance. VPA is subject to therapeutic monitoring 
using total concentrations. Due to non-linear binding of VPA to plasma proteins, current 
dose titration schemes for VPA are empirical. The objectives of this research were to  
1- study the effect of missed/delayed doses on steady state concentrations of VPA and 2-
design a nomogram that can be used for dose titration based on total VPA concentrations.  
             
ix 
  
            Methods. 1- A simulation study was conducted to test for different poor 
compliance scenarios. The effect of missed doses was quantified and used to derive dosing 
recommendations. 2- A clinical study was carried out in healthy volunteers. Nine 
volunteers were administered 500, 750 and 1000 mg VPA in a dose escalation study. A 
nomogram was developed using in vitro plasma protein binding data in all volunteers and 
tested using dose escalation data. Several delayed/missed doses scenarios were tested in 
order to validate the simulation model. 3- A revised simulation model was developed using 
combined information from plasma protein binding and pharmacokinetic analysis of 
clinical study data. 
 
            Results and Discussion. Simulation study: Dosing recommendations in the case of 
a missed or delayed dose are both formulation and dose dependent. Results from the 
clinical study validated the simulation model and the revised simulation model properly 
incorporated intra and inter individual variabilities. 
            VPA nomogram: A one-site saturable binding model provided an adequate 
description of the binding of VPA to albumin. A dosing nomogram for VPA was 
constructed. To avoid the risk of achieving toxic concentrations, the dose should not be 
increased by more than 2 fold at a time. The nomogram should be used in conjunction with 
patient history and clinical response.  
 
            Conclusions. This research provides dosing recommendations to the clinicians to 
counsel patients taking preparations of VPA in the event of a missed dose. The use and 
x 
  
validation of VPA nomogram will foster the rational use of VPA for the treatment of 
epilepsy and its role in other neuropsychiatric disorders. 
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CHAPTER 1 
 
INTRODUCTION AND LITERATURE REIVEW 
 
 
Epilepsy 
 
            About two million Americans have epilepsy (2-4%); of the 125,000 new cases that 
develop each year, up to 50% are in children and adolescents [1]. Epilepsy is a chronic 
condition of various etiologies characterized by a predisposition to recurrent, usually 
spontaneous, epileptic seizures. While a single seizure does not constitute epilepsy, two 
initial seizures occurring within a 24-hour period are considered to have the same 
significance as a single seizure. However, a single seizure accompanied by evidence of a 
cortical lesion (e.g. abnormalities on neurologic examination such as mental retardation or 
on neuro-imaging) or a single seizure accompanied by epileptiform abnormalities on 
electroencephalography (EEG) could serve as basis for the diagnosis of epilepsy. 
Therefore; an epileptic seizure is an abnormal and excessive discharge of brain neurons 
involving hyper-synchrony accompanied by some behavioral change. An Epileptic 
syndrome has been defined as “a clinical entity with relatively consistent clinical features, 
including seizure type(s), etiology, EEG features, neurologic status, prognosis, and, in 
some cases, response to specific antiepileptic drugs “[2].  
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            There are several types of seizure according to the international classification of 
epilepsies [3].  
 
           Simple partial (focal) seizure is caused by a local cortical discharge, which results in 
seizure symptoms appropriate to the function of the discharging area of the brain without 
impairment of consciousness. Simple partial seizures may consist of motor, sensory, 
autonomic, or psychic signs or symptoms, or combinations of these.  
 
           Complex partial (psychomotor, temporal lobe) seizure. The crucial distinction 
between simple partial seizures and complex partial seizures is that consciousness is 
impaired in the latter and not in the former. Impaired consciousness is defined as the 
inability to respond normally to exogenous stimuli, owing to altered awareness or 
responsiveness. At the onset of a complex partial seizure, any of the symptoms or signs 
(motor, sensory, autonomic, or psychic) of a simple partial seizure might happen without 
impairment of consciousness providing an aura. The central feature of a complex partial 
seizure is impairment of consciousness, which may occur with or without a preceding 
simple partial aura. No other symptoms or signs maybe present during the period of 
impaired consciousness or automatisms might appear (i.e., unconscious acts that are that 
“automatic” and of which the patient has no recollection). The attack characteristically 
ends gradually, with a period of postictal drowsiness or confusion.  
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           Absence (petite mal) seizures. These consist of sudden onset and cessation of 
impaired responsiveness, accompanied by a unique 3-Hz spike-and-wave EEG pattern. No 
aura is present, and little or no postictal symptomatology occurs. The majority of absence 
seizures last 10 seconds or less and may be accompanied by clonic, atonic or tonic 
components, automatisms, or autonomic components. Absence seizures usually first 
manifest between the ages of 5 and 12 years and often stop spontaneously in the teens.  
 
           Myoclonic seizures. Consist of brief, sudden muscle contractions that maybe 
generalized or localized, symmetric or asymmetric, synchronous or asynchronous. No loss 
of consciousness is generally detectable.    
 
           Tonic seizures. Consists of a sudden increase is muscle tone in the axial or 
extremity muscles, or both, producing a number of characteristic postures. Consciousness 
is usually partially or completely lost. Prominent autonomic phenomena occur. Postictal 
alteration of consciousness is usually brief but it may last several minutes. Tonic seizures 
are relatively rare and usually begin between 1 and 7 years of age.   
 
           Atonic seizures. Consist of sudden loss of muscle tone. The loss of muscle tone may 
be confined to a group of muscles, such as the neck, resulting in a head drop. Alternatively, 
atonic seizures may involve all trunk muscles, leading to a fall to the ground.  
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           Clonic seizures. Occur almost extensively in early childhood. The attack begins 
with loss or impairment of consciousness associated with a sudden hypotonia or a brief, 
generalized tonic spasm. This is followed by 1 minute to several minutes of bilateral jerks, 
which are often asymmetric and may appear predominantly in one limb. During the attack, 
the amplitude, frequency and spatial distribution of these jerks may vary greatly from 
moment to moment. In other children, particularly those aged 1 to 3 years the jerks remain 
bilateral and synchronous throughout the attack. Postictally, recovery may be rapid, or a 
prolonged period of confusion or coma may ensue.  
 
           Tonic-clonic (grand mal) seizures. Before the tonic phase of a tonic-clonic seizure, 
bilateral jerks of the extremities or focal seizure activity might occur. The onset of the 
seizure is marked by loss of consciousness and increased muscle tone (tonic phase), which 
usually results in a rigid flexed posture at first, and a then a rigid extended posture. This is 
followed by bilateral rhythmic jerks that become further apart (clonic phase). Prominent 
autonomic phenomena are observable during the tonic and clonic phases. In the postictal 
phase, increased muscle tone occurs first, followed by flaccidity. Incontinence may occur. 
The patient awakens by passing through the stages of coma, confusional state, and 
drowsiness.  
 
            Some epilepsies remain unclassified due to lack of data. Another classification of 
seizures is based on etiologies: idiopathic, symptomatic or familial. There is also a 
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classification of epilepsy syndromes. A complete clinical discussion of seizure types and 
diagnosis can be found in many references [3, 4].  
 
Valproic Acid (VPA) 
           VPA was first used in France in 1967. It is effective against most seizures. It is also 
used in bipolar disorders and for migraine prophylaxis [5, 6].  
 
Chemistry  
           VPA (molecular weight = 144.2 g/mol), also called 2-propylpentanoic acid or 
dipropylacetic acid [7], is a C-8 branched chain fatty acid; see chemical structure in figure 
1.1. Divalproex sodium is a common therapeutic form of the drug (e.g. Depakote), it’s a 
coordination compound between sodium VPA and it’s sodium salt in a 1:1 molar ratio. The 
free acid has a Pka of 4.56-4.8 [8].  
 
Routes of Elimination 
            Phase 1. The metabolism of VPA is complex due to the fact that several of the 
metabolites are formed by more than one route [9-14]. For example, 2-ene VPA, 3-OH 
VPA and 3-keto VPA [15] all result from β-oxidation (mitochondria). On the other hand, 
CYP-450 dependent (ω-, (ω-1)- and (ω-2)-hydroxylation transforms VPA to 5-OH-VPA, 
4-OH-VPA, and 3-OH-VPA, respectively [16-18]. Some researchers have suggested CYP-
450 accounts for a large percentage of VPA transformation to 3-OH-VPA [19, 20]. Some 
examples of desaturation (formation of double bonds) resulting from β-oxidation are 2-
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ene-VPA, 3-ene-VPA 2,3`- diene-VPA and 2,4-diene-VPA [19-21]. The 2,4-diene-VPA, 
thought to play a role in the hepatotoxicity of VPA [21-25], is a product of the pathway 
that coverts 4-ene-VPA-CoA ester to the corresponding 2,4-diene-VPA-CoA. Experiments 
with human cDNA-expressed P450 isoforms have shown that multiple human CYP-450 
isoforms are involved in the desaturation of VPA. These include CYP2C9 and CYP2A6 
[25] as well as CYP2B6 [26].  
 
            Phase 2. Glucuronidation is the major pathway of VPA metabolism in several 
animal species [27] and in humans [28-30].  
 
Pharmacokinetics 
            Many studies were conducted to characterize the disposition of VPA [31-39]. Table 
1.1 summarizes the pharmacokinetic parameters of valproic acid in adult volunteers, 
patients with epilepsy and healthy elderly. The pharmacokinetics of VPA are unchanged in 
patients with epilepsy. Therefore, studies in healthy volunteers can be extrapolated to 
patients with epilepsy. Patients on polytherapy have increased clearance and require higher 
doses than monotherapy patients.  
 
Plasma Protein Binding (PPB) 
           VPA PPB has been demonstrated very early. Most authors favor the presence of one 
saturable binding site on albumin [40-42]. A recent paper [43] looked at the PPB of VPA 
following rapid infusions (ex vivo). The authors used a two-saturable biding site model to 
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characterize the binding of VPA to albumin. The analysis assumed the presence of a high 
capacity, low affinity site (N1=1.54± 0.108, Ka1 “association rate constant” =11.9±1.99 
mM-1, equivalent to a dissociation rate constant Kd= 0.084 mM or 12 mg/l) and a second 
low capacity, high affinity site (N2= 0.194±0.0783, Ka2=164±141 mM-1 and Kd= 0.006 
mM or 0.88 mg/l). There is significant doubt around the presence of the second binding 
site. The overall effect of PPB of VPA in terms of contribution of binding sites does not 
seem to differ whether the saturable binding is accounted for through one or two sites 
(computer simulations results). The presence of two sites versus one site will be challenged 
in an in vitro study to characterize the protein binding of VPA in human plasma.  
 
            Since the PPB of VPA is saturable, the free fraction increases with total 
concentration. This means that the clearance and volume of distribution of total VPA 
increase as the free fraction increases. Since there is no evidence of saturable metabolism, 
the pharmacokinetics of free VPA are linear. The clearance and volume of distribution of 
free VPA remain constant as the dose increases. Since VPA has is a low hepatic extraction 
ratio drug, as the free fraction increases; total VPA concentration decreases while the 
concentration of free VPA increases slightly [44]. 
 
Concentration-Response Relationships 
            It is recognized through clinical experience with VPA that there is not a clear 
correlation between concentration and clinical efficacy; mainly seizure control. This 
reflects the fact that VPA has a relatively narrow therapeutic index and might have a 
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different therapeutic index in each patient [45]. A therapeutic range of 50-100 mg/l based 
on total concentrations has been used for a while [46]. There is trend nowadays to broaden 
the therapeutic range to 50-150 mg/l [3] based on evidence from clinical practice that some 
subjects require concentrations in that range for therapeutic benefit. There have been recent 
attempts to find pharmacodynamic markers to relate VPA dose to its effect for use in 
therapeutic drug monitoring. Using VPA monotherapy, it was shown that there is no 
relationship between VPA dose and EEG changes, multiple sleep latency test (MSLT), 
critical flicker fusion test (CFF) and other neurophysiologic tests in juvenile myoclonic 
epilepsy [47, 48].  
 
Activity against Epilepsy 
            In 1978, VPA was approved for absence seizures. Efficacy in the treatment of 
absence seizures was compared to ethosuximide [49, 50]. VPA and ethosuximide were 
equally effective in epileptics with who are being treated for the first time. VPA is also 
effective against convulsive seizures. Children with generalized tonic-clonic seizures often 
respond to monotherapy with VPA [51].  VPA is recognized as the drug of first choice 
against myoclonic seizures [52]. Use in the symptomatic generalized epilepsies (Lennox-
Gastaut syndrome) is not as successful neither is the use for prevention of infantile spasms 
occurring as part of West’s syndrome. VPA has some activity against partial seizures, 
febrile seizures and status epilepticus [53]. 
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Activity against other Conditions 
           Migraine. Several double blind, placebo-controlled studies have shown that VPA is 
effective against migraine [54-56]. VPA reduces migraine attacks frequency, duration and 
intensity in some cases. The fact that migraine and epilepsy co-exist commonly in patients  
facilitated the discovery of the therapeutic benefit of VPA. FDA approved VPA for use 
against migraine in 1996 [57].  
 
           Other Conditions. This includes activity against acute mania, depression, bipolar 
disorder, anxiety disorders, schizoaffective disorders and behavioral problems associated 
with dementia in elderly. More empirical uses for VPA continue to arise [58].  
 
Mechanisms of Action 
            Since VPA has a wide spectrum of activity against epilepsies and other neuro-
psychiatric disorders, it is thought to act through a combination of mechanisms. There is 
no agreement on the exact mechanism of action of VPA. VPA modulates gamma amino 
butyric acid (GABA) turn over and potentiates GABAergic functions in different regions 
of the brain [59], limits depolarization-induced sustained repetitive firing by an effect on 
voltage-sensitive sodium ion channels [60] and has an effect on calcium conductance [61]. 
VPA has an effect on the neuronal excitation mediated by the NMDA subtype of glutamate 
receptors, which may play a role in its antiepileptic effect [62]. 
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Adverse Effects  
           VPA is one of the better studied neuropsychiatric agents in terms of side effects. 
Side effects range from mild to sometimes severe effects. Due to the multiple mechanisms 
of action of VPA, much is still to be found about the causes of these adverse events, their 
relation to the VPA concentration and the nature of some idiosyncratic reactions some 
patients may be more susceptible to than others. The major side effects of VPA include  
liver toxicity, which may be fatal and teratogenic effects. The following summarizes the 
side effects often encountered in clinical practice [63]. 
 
            Gastrointestinal (GI) side effects. Nausea, vomiting, and dyspepsia are among the 
most common. These symptoms might occur in up to 25% of the population but are 
reduced by the use of the controlled-release preparation as Depakote Extended release and 
delayed release (enteric coated). Usually seen at initiation of therapy. 
 
           Weight gain. A frequent side effect might be severe to require discontinuation of 
treatment. Can be counteracted by conscious reduction of caloric intake. 
       
            Hair change. Occasional, in terms of hair thinning or alopecia (hair loss). 
 
            Tremor. During long-term valproate therapy, seen in 10% of the patients. Rarely is 
sufficiently severe to limit treatment. Experience indicates that it’s dose-related [64]. 
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            Other neurological side effects. Somnolence (drowsiness), acute confusional states 
and irritability; these are usually seen with poly therapy. Sedation alone occurs in 2% of 
the patients. Effects on cognition might be associated with higher doses. 
 
            Metabolic disturbances. Hyperammonemia is common after valproate 
administration, may or not be associated with hepatic (liver) dysfunction. VPA 
Concentrations higher than 100 mg/l increase incidence [65]. Other metabolic disturbances 
include hyperglycinemia and hyperglycineyurea, with no clinical symptoms. 
      
            Transient amenorrhea. In young women after initiation of valproate therapy, may 
persist up for a year. 
 
            Idiosynctratic reactions. Hematologic (blood) side effects such as neutropenia, bone 
morrow suppression, thrombocytopenia and inhibition of platelets in the clotting process.  
 
            Hepatotoxicity. Usually in the form of dose-related elevation in liver enzymes in 
40% of the patients, but not associated with clinical symptoms and is usually transient. 
May be dose related.  It’s believed that it might reflect enzyme induction rather than 
hepatotoxicity.  
 
            Hepatic failure. Overall incidence of 1/10,000 [66]. The primary risk, however, is 
for children under 2 years of age receiving valproate as poly therapy. The risk in this group 
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has a rate of 1/500. For patients older than 2 years this risk declines to 1/12,000. When 
valproate was given as mono therapy the risk of fatality from liver failure is 1/37,000 for 
all mono therapy patients [67], although it was still 1/7,000 for ages 0-2 years. Patients on 
valproate mono therapy older than 2 years had a fatality rate of 1/45,000. Clinical features 
associated with hepatic toxicity are nausea, vomiting, anorexia, jaundice and lethargy 
sometimes accompanied by edema.  
 
            Pancreatitis. Acute and is occasionally fatal. Complications may include pericardial 
infusion, laparotomy and wound infection. This condition is usually reversible with 
withdrawal from valproate.  
 
            Teratogenicity. In the form of neural tube defect. The occurrence rate in children 
born to epileptic mothers taking valproate is approximately 1-2%. Most maternal 
exposures to valproate do not appear to have adverse outcomes. May be related to high 
VPA concentrations. 
 
Formulations and Routes of Administration 
            VPA can be administered orally, intravenously and rectally. It’s available as a 
capsule (Deproic), soft gelatin capsule (Depakene) of 250 mg and syrup (250mg / 5ml) as 
sodium salt. Intravenous formulation of sodium salt (Depacon, 100 mg / ml) is also 
available. One common therapeutic form is divalproex sodium; supplied as tablets (125, 
250 and 500 mg) available as Depakote sprinkle capsules, delayed-release (DR) and 
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extended release (ER) tablets [5]. The ER formulation is formulated as a hydrophilic 
polymer matrix controlled-release tablet system to provide more consistent blood 
concentrations over 24 hours. This system results in the release of drug in the stomach, 
small intestine, and large intestine over an 18- to 24-hour period of time. The DR 
formulation is enteric coated and thus is stable in the stomach but dissolves in the small 
intestine and thus minimizes gastro-intestinal side effects associated with immediate-
release forms of VPA. 
 
Dosing Recommendations 
            For epilepsy, the recommended dose for monotherapy is 10-15 mg/kg daily. The 
dose is then increased as needed by 5-10 mg/kg/day increments, as tolerated. Doses in the 
range of 30-60 mg/kg/day are needed for Polytherapy [53].  
            
            For migraine, start with 250 mg/day and then increase to 500 mg/day and 750 
mg/day if needed [68]. For other psychiatric conditions, start at 20-30 mg/kg/day and 
increase dose based on tolerance and response [58].  
 
Clinical Trial Simulation (CTS) 
            CTS is being increasingly used as a fundamental tool in drug development. CTS 
aids in the design of clinical studies with an overall goal of improving the efficiency of 
drug development. With introduction of population-based modeling, a better understanding 
of the impact of variability encountered in clinical studies has evolved and now there are 
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mathematical methods to quantify this variability. CTS uses the models established in 
population modeling and the values obtained as quantifiers of the intra- and inter- subject 
variabilites to look at hypothetical scenarios both for pharmacokinetics and 
pharmacodynamics. CTS can also be used to improve the power of different studies 
through design optimization. As such, CTS is essentially an application of Monte Carlo 
Methods, which find uses in aerospace, engineering, physics and chemistry.  
 
            The simulation model consists of an Input-Output Model which is in this case is a 
Pharmacokinetic model. The pharmacokinetic model is called a structural model.  
The element of parameter variability will be as a stochastic model. The stochastic model 
includes: a) a population parameter variability comprising between-subject and within-
subject variability in model parameters. In practical terms, within-subject variability is 
largely defined by between-occasion variability but includes stochastic variation in 
parameters, such as clearance, that may occur within an occasion (within-occasion 
variability). A term often used for population parameter variability is inter-individual 
variability. b) Residual unexplained variability accounts for model misspecification and 
measurement error. A term often used for residual unknown variability is intra-individual 
variability [69].  
 
            The other part of the simulation model is called covariate distribution model, which 
determines the distribution of the demographic covariates in the trial subject sample (age, 
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weight etc.). The last part of the model is the trial execution model [69]. For example, the 
simulation protocol will incorporate different scenarios of poor compliance. 
             
            Technically speaking, In order to perform a Monte Carlo simulation, the sampling 
distribution of the model parameters (inputs) must be defined a priori, for example a 
normal distribution with mean µ and variance σ2. Monte Carlo Simulation repeatedly 
simulates the model, each time drawing a different set of values (inputs) from the sampling 
distribution of the model parameters, the result of which is set of possible outcomes 
(outputs). The usual source for information on the distribution and covariance between the 
pharmacokinetic parameters is the result of a population pharmacokinetic analysis where 
an underlying structural pharmacokinetic model has been established and an assessment of 
the distribution; inter- and intra-individual variability of a set of pharmacokinetic 
parameters has been defined [70].  
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Research Objectives 
            This dissertation aimed to address the following:  
 
            First, the effect of missed doses on steady state concentrations of VPA (total and 
free) following the administration of Depakote extended release (ER) and Depakote 
delayed release (DR) was characterized using simulations.  
 
            Secondly, a nomogram for VPA that can be used to titrate VPA doses based on 
total concentrations to compensate for missed/delayed doses was developed. The 
nomogram was constructed using nonlinear plasma protein binding data and tested a in a 
clinical trial. 
 
            Thirdly, a simulation model that properly incorporates intra- and inter-individual 
variabilities in unbound and bound VPA was developed, validated and can be used to make 
dosing recommendation in the case of missed/delayed doses 
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Clinical Significance 
            Clinicians are divided on how to replace doses during therapy with VPA and it’s 
unethical to withhold therapy from patients with epilepsy to explore the effect of missed 
and delayed doses. This research provides dosing recommendations to the clinicians to 
counsel patients taking preparations of VPA in the event of a missed dose. The use and 
validation of VPA nomogram will foster the rational use of VPA for the treatment of 
epilepsy and its role in other neuropsychiatric disorders.   
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Table 1.1 Pharmacokinetics of VPA in healthy adults, patients with epilepsy and elderly. 
       
Clearance 
(L/h/kg) 
 
 
Category 
 
Study 
Number of 
subjects 
 
Mono/Poly 
Therapy 
 
VPA Regimen 
 
Vd (L/kg) 
Total  
 
T1/2 (h) 
 
Total 
VPA  
 
Free 
VPA 
 
Healthy 
adults (< 
60 years) 
 
Perucca et 
al.31, n=6  
 
N/A 
 
Single dose 
(800 mg) 
ORAL 
 
0.14± 0.02 
 
13.0± 2.4 
 
0.0077± 
0.0015 
 
0.127± 
0.029 
  
Bialer et al.32, 
33, n=6 
 
N/A 
 
Single dose 
(1000 mg) 
ORAL 
 
0.14± 0.02 
 
14.9± 2.4 
 
0.0067± 
0.0014 
 
0.17± 
0.46 
  
Gugler et 
al.34, n=6 
 
N/A 
 
Steady state 
(1200) mg/day 
ORAL 
 
0.15± 0.02 
 
15.9±2.6 
 
0.0064± 
0.0011 
 
- 
  
Bowdle et 
al.35, n =6 
 
N/A 
 
Steady State 
(500 mg/day) 
ORAL 
 
0.13± 0.02 
 
13.6±2.8 
 
0.0067± 
0.0013 
 
0.089± 
0.071 
 
Patients 
with 
epilepsy 
 (<60 
years) 
 
Miljkovic et 
al.36, n=10 
 
Mono 
therapy 
 
Single dose 
(900 mg) 
ORAL.  
 
0.20± 0.04  
 
15.0± 4.0 
 
0.0094± 
0.0029 
 
- 
  
Sundqvist et 
al.37, n=16 
 
Mono 
therapy 
 
Steady State 
(500 mg b.i.d) 
ORAL 
 
- 
 
- 
 
0.011± 
0.003 
 
0.126± 
0.044 
   Steady State 
(1000 mg b.i.d) 
ORAL 
- - 0.015± 
0.004 
0.118± 
0.067 
  
Perucca et 
al.38, n=6 
 
Poly 
therapy 
 
Single dose 
(800 mg) I.V  
 
0.18± 0.03 
 
9.0± 1.4 
 
0.015± 
0.006 
 
- 
   Single dose 
(800 mg) 
ORAL  
0.18± 0.03 9.0± 1.2 0.0176± 
0.0028 
- 
  
Schapel et 
al.39, n=17 
 
Poly 
therapy 
 
Single dose 
(600 mg) 
ORAL 
 
0.19± 0.09 
 
9.3± 2.0 
 
0.015± 
0.0058 
 
- 
 
Healthy 
elderly 
(>60 yrs) 
 
Perucca et 
al.31, n=6  
 
N/A 
 
Single dose 
(800 mg) 
ORAL 
 
0.16± 0.02 
 
15.3± 1.7 
 
0.0075± 
0.0022 
 
0.078±
0.015 
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Figure 1.1 Chemical structure of valproic acid. 
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            ABSTRACT. Divalproex sodium extended-release (Depakote® ER) is a once 
daily (QD) formulation for valproic acid that was developed to improve patient 
compliance and reduce side effects compared to the standard twice-daily (BID) delayed 
release (DR) formulation (Depakote® tablets). However, there are concerns of potential 
sub-therapeutic concentrations following delayed or missed doses or toxic concentrations 
with replacement doses for the ER and DR formulations. Simulations can be used to 
investigate the effect of poor compliance on drug concentrations, which may not be 
possible to do in a study population due to ethical or practical reasons. Using Monte 
Carlo simulations, the effect of different patterns of poor compliance on ER QD and DR 
BID were systematically characterized. Non-linear binding of valproic acid to albumin 
was incorporated into the model, and the results were based on total and unbound VPA 
for comparison. The effect of poor compliance is less significant on DR BID compared to 
ER QD. Dosing recommendations in the case of a missed or delayed dose are both 
formulation and dose dependent. Since total VPA concentrations show higher inter-
individual variability and tend to under-estimate the effect of poor compliance; the use of 
unbound VPA concentrations may offer an advantage in therapeutic monitoring.  
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Introduction 
            Valproic acid (VPA) is a broad-spectrum antiepileptic drug effective against a 
wide variety of seizures, including complex partial, tonic-clonic convulsive, absence and 
myoclonic seizures. It is also active against neonatal seizures, febrile seizures and status 
epilepticus. Valproic acid is also used in the treatment of bipolar disorders and for the 
prophylaxis of migraine headaches [1].  
 
            VPA is rapidly absorbed from its oral forms and has no first pass metabolism. It 
binds to plasma proteins and this binding is concentration dependent. As such, the free 
fraction of VPA increases from 10% at 40 mg/l to 18.5% at 130 mg/l [1]. The plasma 
protein binding of VPA decreases in the elderly, hepatic and renal impairment and in the 
presence of other medications that have higher binding affinity to the same binding site 
on albumin e.g. aspirin. This non-linear binding renders the kinetics of the total VPA 
non-linear i.e. the total concentration increases less than proportionally with the dose and 
the clearance and volume of distribution of total VPA increase with the free fraction. The 
kinetics of the unbound drug are linear. VPA is metabolized almost entirely by the liver. 
30-50 % of the dose is appears in the urine as glucuronide conjugate. Mitochondrial β-
oxidation is the other major pathway accounting for over 40% of the dose. Less than 15-
20 % of the dose is eliminated by other oxidative mechanisms and less than 3% of the 
dose is eliminated as the unchanged drug in the urine [1]. Mean plasma clearance and 
volume of distribution for total valproate are 0.56 L/h and 11 L respectively. For free 
valproate mean plasma clearance and volume of distribution are 4.6 L/h and 92 L.  Mean 
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terminal half-life for valproate mono therapy ranged from 9-16 hours following oral 
doses of 250-1000 mg [1].  
 
            Divalproex sodium extended-release (Depakote® ER) is a once daily (QD) VPA 
formulation that was developed to improve patient compliance and reduce side effects 
compared to the standard twice-daily (BID) delayed release (DR) formulation 
(Depakote® tablets). The ER formulation is formulated as a hydrophilic polymer matrix 
controlled-release tablet system to provide more consistent blood concentrations over 24 
hours. This system results in the release of drug in the stomach, small intestine, and large 
intestine over an 18- to 24-hour period of time. The DR formulation is enteric coated and 
thus is stable in the stomach but dissolves in the small intestine and thus minimizes 
gastro-intestinal side effects associated with immediate-release forms of VPA. 
 
            Compliance with anti epileptic drug therapy is a major determinant of successful 
treatment [2, 3]. It has been shown that once daily dosing improves patients’ adherence to 
medication and thus therapeutic outcomes [4]. Although once daily administration offers 
more convenience, there are concerns about using a QD regimen for an antiepileptic drug 
such as VPA. If a patient misses a dose, there is the possibility of attaining sub-
therapeutic drug concentrations, which could lead to break-through seizures. Further, if 
the next dose is doubled, drug concentrations may rise above the therapeutic index 
leading to central nervous system (CNS) toxicity. This being the case, there is a need to 
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determine the effect of poor compliance on the VPA concentrations following 
administration of the ER and DR formulations. 
            
            It is unethical to purposefully withhold doses from patients with epilepsy to 
determine the effect of poor compliance on drug concentrations. An alternative approach 
to studying poor compliance is to use computer simulations. To account for inter-
individual variability, the simulations should generate a hypothetical population. This can 
be achieved using Monte Carlo simulations, which involve the deliberate use of random 
numbers in a calculation that has the structure of a stochastic process [5]. This stochastic 
process can be used to study the long-term effect in model variability on the outcome of 
the model [6]. Once the hypothetical population is generated, poor compliance scenarios 
can be introduced artificially by delaying doses from schedule, missing doses and adding 
make-up doses to the schedule. The effect of poor compliance on the population can then 
be studied quantitatively.  
 
            The purpose of this study was to study the effect of delaying, missing and 
replacing doses on VPA concentrations following both the ER and DR preparations using 
Monte Carlo simulations. The results will improve the clinicians’ ability to consult 
patients if they delay or miss a dose of VPA. 
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Methods 
Study Design 
            Each simulation included 100 hypothetical subjects. The random seed was set 
manually to (230, 240, 120, 100). The model parameters used were derived from an adult 
population and there were no covariate (age, weight, gender) distribution models for the 
virtual trial population. Subjects were assumed to be healthy and on valproate mono 
therapy. The simulations assumed that the extended release (ER) formulation was 
administered once daily and delayed-release (DR) preparation was administered twice 
daily. Unbound and total valproic acid concentrations were simulated from the time of 
dose administration to 280 h. The simulations were based on the administration of 1000 
mg ER once daily, 500 mg DR twice daily, 2500 mg ER once daily and 1000 mg DR 
twice daily.  
 
            Hypothetical populations were generated at steady state for each drug 
administration schedule. Briefly, values for pharmacokinetic parameters means and 
estimates of variability were obtained from the literature and used to generate plausible 
parameters ranges based on a normal or lognormal distribution. The trial simulator 
software would then draw a set of parameters for each subject that defines its 
concentration time profile. Different poor-compliance scenarios were introduced to 
concentration-time profiles at steady state with one or two missed, delayed and 
replacement doses from schedule. For once-daily regimens, simulations’ scenarios 
included doses taken 6, 12, 18, 24 hours late from schedule and then two doses taken 24 
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hours late (replacement dose for the missed dose), see Figure 2.1 for demonstration of 
doses. For twice-daily regimens, doses were simulated 3, 6, 9, 12 hours late from 
schedule and then two doses were simulated 12 hours late (replacement dose for the 
missed dose). More extreme cases where two doses are delayed at various time or missed 
were also simulated. 
 
Structural model 
            A one-compartment model with first order elimination was used to simulate 
unbound VPA concentrations. The two formulations differ only in the input function: the 
ER formulation is accounted for through a zero order input over 22 hours with 89% 
bioavailability [7]. The DR formulation absorption is characterized by a 2 h lag time 
(tlag= 2 h) followed by first order absorption rate (ka= 0.1 h-1). The bioavailability of the 
DR preparation is assumed to be complete (F=1) [8].  
 
            Equation 1 was used to simulate unbound VPA concentrations (Cu) following 
administration of the DR preparation and equation 2 was used to simulate Cu following 
the ER formulation: 
Cu= (ka* D / V (ka – CLu/Vu) (e – CLu/Vu t - e – kat)    eq.1   
Cu= F*D/CLu*T (eCLu/Vu *T –1) e – CLu/Vu t                 eq.2  
where D is the dose, Vu is the volume of distribution of unbound drug, CLu is the 
systemic clearance of unbound drug, F is bioavailability, ka is the first order absorption 
rate constant for DR and T is the duration of the zero order input for ER [9]. 
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The following equation was used to calculate the total VPA concentrations (Ct) [7]: 
Ct= Cu + (N1K1CuP)/(1+K1C1) + (N2K2CuP)/(1+K2Cu)   eq.3 
Where P is albumin concentration, N1 and K1 and N2 and K2 are the number of binding 
sites and equilibrium association constants for a low affinity - high capacity binding site 
and high affinity - low capacity binding site, respectively.  
 
Parameters and Parameter Distributions 
            Random pharmacokinetic parameter means ±SD and a priori distributions of 
random model parameters were used for the simulations.   Geometric means ± SD for 
CLu and Vu were 5.04 ±1.00 L/h and 95.1 ± 19.0 L, respectively [1].   These parameters 
were assumed to by distributed log-normally.  Protein binding parameters (obtained ex 
vivo) [5], assumed to be normally distributed, were: N1 = 1.54 ± 0.108, K1 = 11.9 ± 1.99 
mM-1, N2 = 0.194 ± 0.0783, K2 = 164 ± 141 mM-1, and P = 0.528 ± 0.0528 mM.  Limits 
of ± 2 standard deviations were placed on all parameters for the simulations (this will 
allow inclusion of a reasonable ~ 95% of the population generated while avoiding 
contamination from outliers).  
 
            The simulations were performed using Pharsight® Trial Simulator TM (Pharsight 
Corporation, Mountain View, CA) which uses Monte Carlo simulations based on a 
stochastic model to approximate the distribution of probable outcomes for a clinical trial 
[11].  
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Summary of simulations’ outcomes 
            VPA concentration-versus time profiles were generated for each scenario. Drug 
concentrations were compared to the therapeutic range of valproic acid. Based on total 
VPA, a therapeutic range of 50-150 mg/l was assumed [1, 12]. The lower limit for the 
therapeutic range for unbound VPA was 5 mg/l; (at total concentrations of 50 mg/l, 
almost 90% of the binding sites are occupied [1], therefore the free fraction is = 10%). 
There is no accepted upper limit for the therapeutic range of unbound VPA. In order to 
assess the effect of missed or delayed doses, the simulations’ outcomes were summarized 
by: 
1- Number of subjects with sub-therapeutic concentrations after delayed or missed 
doses quantified as the percentage of subjects having total drug concentrations 
lower than 50 mg/l or unbound VPA concentrations less than 5 mg/l. Sub-
therapeutic subjects at base line steady state were excluded from poor adherence 
scenarios. 
2- The time range that subjects spent in the sub-therapeutic range or ‘time at risk’, in 
hours, which is essentially the duration of time where subjects might be at risk of 
breakthrough symptoms.  
3- Number of subjects with drug concentrations above the upper limit of the 
therapeutic range quantified as the percent of subjects with total VPA 
concentrations exceeding 150 mg/l. This percentage reflects the probability of 
potential toxicity. 
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Results  
            Figure 2.2 shows the simulated unbound and total valproic acid concentrations 
following administration of 2500 mg daily of the ER preparation; ER dose on day 7 was 
administered six hours late from schedule (30 hours after the last dose on day six). Figure 
2.3 shows the effect of missed dose followed by a double up on dose. The results of the 
scenarios for subjects taking 1000 and 2500 mg ER on a once daily regimen are 
summarized in Table 2.1. The percentage of subjects on ER 1000 mg that had sub-
therapeutic concentrations due to poor compliance varied from (43-100%) with respect to 
Cu (< 5mg/l) and from (28-100%) with respect to Ctot (<50 mg/l). The mean times at risk  
varied from (6-60 h) with respect to Cu and from (8-53 h) with respect to Ctot. None of the 
subjects on ER 2500 mg QD had sub-therapeutic concentrations even if one dose is 
delayed six hours from schedule. Almost 50% of the population had sub-therapeutic 
concentrations if one dose (ER 2500) is missed from schedule while all subjects will be 
sub-therapeutic if two doses are missed. The mean time at risk varied from (0-28 h). 
Regarding potential toxicity (Ctot >150 mg/l), 52% of the population might experience 
toxic concentrations if two doses are taken 66 h after last dose while on ER 2500 mg QD.  
 
            Table 2.2 shows results for subjects taking 500 and 1000 mg DR on a twice-daily 
regimen. For DR 500 mg BID, the percentage of subjects that had sub-therapeutic 
concentrations due to poor compliance varied from (3-88 %) with respect to Cu and from 
(3-77%) with respect to Ctot. The mean time at risk varied from (1-14 h). None of the 
subjects experienced sub-therapeutic concentrations if one dose is delayed or missed 
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from a DR 1000 mg BID regimen. However, if two doses are delayed from schedule, 1-
24 % of the population might have sub-therapeutic concentrations. The mean time at risk 
varied from (2-6 h). 
 
            Dosing recommendations following missed doses of ER and DR VPA 
formulations are shown in Tables 2.3 and 2.4, respectively.   
 
Discussion 
            Epilepsy is a chronic condition of various etiologies characterized by a 
predisposition to recurrent, usually spontaneous, epileptic seizures. About two million 
Americans have epilepsy; of the 125,000 new cases that develop each year, up to 50% are 
in children and adolescents [13]. Where there are several therapeutic alternatives for 
epilepsy, VPA remains one of the most widely used antiepileptic drugs. VPA is also used 
for other neuropsychiatric disorders such as migraine prophylaxis, bipolar disorder and 
mania.  
             
            Maintaining VPA concentration in the therapeutic range will determine the 
effectiveness of chronic therapy for patients with epilepsy. It is well recognized that 
patients will miss doses and that “ideal” steady state generated by computer models after 
multiple dosing is a rare finding in clinical practice. Although missing doses from the 
therapeutic regimen has been recognized as a random process with no specific patterns, it 
is possible to assume some general yet representative scenarios for missed doses that will 
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allow formation of dosing recommendations in the case a missed dose occur. In this study 
we introduced several representative and realistic scenarios to quantify the effect of 
missed doses on VPA concentration in the case of chronic monotherapy.  
 
            The effect of delayed or missed doses on steady state VPA concentrations 
depends on the dose and formulation administered. At a dosing regimen of ER 1000 mg 
QD, VPA concentrations in every subject in the hypothetical population hit the sub-
therapeutic range when one dose was missed. This was due largely to steady state total 
drug concentrations for all subjects of less than 100 mg/l. For the higher dose of 2500 mg 
ER QD, the effect of delaying a dose was negligible for up to 12 hours after the last dose. 
Nevertheless, almost 50% of subjects had sub-therapeutic concentrations in the case of a 
missed dose while on 2500 mg QD.  
            
            The effect of delaying or missing two doses is more pronounced for both dose 
concentrations (ER 1000 and 2500 mg QD). For ER 1000 mg QD, there is a considerable 
risk of sub-therapeutic concentrations and the two missed doses must be replaced as soon 
as possible. Risk for sub-therapeutic concentrations for the 2500 mg QD is reduced since 
subjects have higher drug concentrations to begin with. Making up for two doses (one 
missed, one delayed) did show a significant risk of toxicity when two doses of ER 2500 
mg are taken 54 h (14%), 60 h (32%) and 66 h (52%) after last dose, where numbers in 
brackets refer to percentage of subjects that have total VPA concentrations greater than 
150 mg/l.  
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            VPA concentrations after DR 500 mg BID were slightly higher for the overall 
population compared to ER 1000 mg QD because of the lower bioavailability of the ER 
formulation. It is the expectation that the effect of poor compliance in terms of delaying 
or missing a dose would be less pronounced on DR in terms of average times spent in the 
sub-therapeutic range or time at risk, which is the case.  
 
            On the higher DR dose of 1000 mg BID, there is virtually no risk of sub-
therapeutic concentrations even after a dose is missed with no replacement. Dose double 
up did not result in toxicity. Taking two doses of DR 1000 mg at various times after the 
last dose up to 36 hours didn’t elevate VPA concentrations to the toxic range. 
 
            We based our conclusions on both unbound and total VPA. Total and unbound 
VPA plasma concentrations can be determined using a commercially available 
fluorescence polarization immunoassay (FPAI) on the TDx/TDx FLx system from Abbott 
Laboratories. Despite this, clinicians rely on total VPA concentrations to individualize 
therapy with valproic acid. The simulations showed that the times at risk based on total 
VPA are wider than the ones based on unbound VPA; reflecting the added variability 
arising from inter-individual variability in protein binding. It also seems that numbers of 
subjects in the sub-therapeutic range tended to be less when based on total VPA. This 
means that the effect of delayed and/or missed doses can be under-estimated when based 
on total VPA: patients may still seize but Ctot seems to be in the therapeutic range. Since 
it is generally accepted that, the unbound form of the drug is associated with therapeutic 
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actions and adverse effects; unbound valproic acid concentrations may offer an advantage 
when used for therapeutic drug monitoring. 
 
            This simulation study has several limitations. Monte Carlo simulations generate 
hypothetical populations with certain characteristics based on a structural model. Intra- 
and inter-individual variability are introduced into the virtual trial population and do not 
necessarily reflect the overall population. Although the simulations performed scan a 
wide range, there are some subjects in real practice that are not necessarily accounted for. 
The introduction of covariates into the model will make inferences from these 
simulations more specific to certain sub populations. While the therapeutic range for 
VPA is believed to be between 50-150 mg/l based on total VPA, it should be realized that 
some patients with epilepsy have a higher minimally effective concentration. These 
patients usually require higher doses than regular doses. Unfortunately, there is no clear 
relationship between VPA concentrations and clinical effect that has been demonstrated 
so far [1]. This hindered the use of a PK/PD model in our simulations. Another important 
point to consider is that mono therapy or un-induced state was assumed. This study 
cannot be extrapolated to patients on poly-therapy. 
 
Summary 
            This study reports a systematic investigation of the outcome of poor compliance 
on once daily ER and twice daily DR formulations using computer simulations. Higher 
doses of the ER preparation (2500 mg QD) can be used to provide adequate seizure 
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control with dose delays up to 12 hours. For unstable seizure patients, it is recommended 
that patients maintain a twice-daily regimen since twice-daily regimens are less 
susceptible to fluctuations in steady-state concentrations in the case of poor-compliance. 
Having a shorter dosing interval, twice daily regimens demonstrate better maintenance of 
drug concentrations in the case of delayed or missed doses. 
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Appendix 
Derivation of eq 2:  Cu= F*D/CLu*T (eCLu/Vu *T –1) e – CLu/Vu t where 
CLu/Vu =K and F*D/CLu*T= FKo/VuK, where Ko is the input rate in unit/time 
This equation can be shown to account for pre and post release phases as follows: 
- If t<T then release occurred for time=t 
Cu= FKo/VuK (e Kt –1) e – K t, so Cu= FKo/VuK (e (K-K)t – e – K t) which reduces to 
Cu= FKo/VuK (1 – e – K t) this is also = Cmax. It is clear that this same equation holds if 
t=T. 
- If t>T, and t* is time after input ends (t=T+t*), now T is a constant referring to the 
duration of input 
Cu= FKo/VuK (e KT –1) e – K(T+ t*) ) follows that 
 Cu= FKo/VuK (e K(T-t*-T) – e – K(t+T*) ) and 
Cu= FKo/VuK (e K(-t*) – e – K(T+t*) ) so 
Cu= FKo/VuK (e K(-t*) – e – KT * e – Kt*) which after taking e – Kt* as a common factor 
becomes 
Cu= FKo/VuK e K(-t*) (1– e – KT ) or Cu= FKo/VuK (1– e – KT ) e -Kt*  where  
FKo/VuK (1– e – KT ) = Cmax 
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Table 2.1 Summary of simulations scenarios for once daily ER
ER 1000 mg Cu Ctot  
One dose taken ‘x’ hour after 
last dose 
% Sub 
therapeutic 
(<5 mg/l) 
Time at risk 
hours 
% Sub- 
therapeutic 
(<50 mg/l) 
Time at risk 
hours 
% Subjects 
with Ctot > 
150 mg/l 
  Range Mean  Range Mean  
30 43 1-20 6 28 1-24 8 0
36 78 1-25 13 65 1-26 12 0
42 90 1-27 18 82 2-29 16 0
48, missed dose 96 1-53 28 81 1-52 26 0
48, two doses 96 1-29 20 83 1-32 19 0
Two doses taken ‘x’ h after 
last dose 
       
54 100 7-37 28 100 1-40 25 0
60 100 14-44 34 100 6-47 31 0
66 100 21-48 40 100 13-50 37 0
72, two doses 100 28-54 46 100 9-59 43 0
72, one dose 100 39-83 60 100 19-86 53 0
ER 2500 mg Cu Ctot  
One dose taken ‘x’ hour after 
last dose 
% Sub 
therapeutic 
(<5 mg/l) 
Time at risk 
hours 
% Sub 
therapeuti
c 
(<50 mg/l)
Time at risk 
hours 
% Subjects 
with Ctot > 
150 mg/l 
  Range Mean  Range Mean  
30 0 0 0 0 0 0 1
36 3 1-3 5 2-4 3 2
42 20 1-11 5 16 1-12 6 5
48, missed dose 46 2-17 8 47 1-24 8 0
48, two doses 51 1-17 7 46 1-17 7 8
Two doses taken ‘x’ h after 
last dose 
       
54 73 1-23 11 68 1-23 11 14
60 84 1-29 12 80 3-30 15 32
66 91 1-35 21 88 3-37 20 52
72, two doses 91 1-41 26 92 1-46 25 3
72, one dose 100 1-42 28 95 3-43 27 0
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Table 2.2 Summary of simulation scenarios for twice daily DR. 
DR 500 BID Cu Ctot 
One dose taken ‘x’ hour after last dose   
 % Sub- therapeutic 
(<5 mg/l) 
Time at risk 
hours 
% Sub- therapeutic 
(<50 mg/l) 
Time at risk 
hours 
  Range Mean  Range Mean 
15 3 N/A 1 3 1-4 2.5 
18 11 1-7 4 10 1-12 5 
21 25 1-10 5 21 1-13 5 
24, missed dose 39 1-33 12 34 1-37 12 
24, two doses 39 1-13 6 29 1-16 7 
 Two doses taken ‘x’ hour  after last dose       
27 64 1-17 7 43 1-21 8 
30 76 1-21 10 61 1-25 9 
33 90 1-23 12 75 1-26 11 
36 88 2-29  14 77 1-31 14 
DR 1000 BID Cu Ctot 
One dose taken ‘x’ hour after last dose % Sub therapeutic 
(<5 mg/l) 
Time at risk 
hours 
% Sub therapeutic 
(<50 mg/l) 
Time at risk 
hours 
  Range Mean  Range Mean 
15 0 N/A 0 0 N/A 0 
18 0 N/A 0 0 N/A 0 
21 0 N/A 0 0 N/A 0 
24, missed dose 0 N/A 0 0 N/A 0 
24, two doses 0 N/A 0 0 N/A 0 
Two doses taken ‘x’ hour after last dose       
27 1 2 2 4 2-3 2.2 
30 5 1-6 3 19 1-8 4 
33 19 1-9 3 15 1-11 5 
36 24 1-11 6 22 1-13 6 
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Table 2.3 Dosing recommendations for ER based on free VPA. 
ER 1000 mg QD 
One dose taken ‘x’ hour after 
last dose 
Dosing Recommendation 
30 Take dose and resume dosing 
36 Take dose and resume dosing 
42 Take dose and resume dosing 
48, missed dose Take make-up dose 
48, two doses Take doses and resume dosing
Two doses taken ‘x’ h after 
last dose 
 
54 Take doses and resume dosing
60 Take doses and resume dosing
66 Take doses and resume dosing
72, two doses Take doses and resume dosing
72, one dose Take two doses and resume 
ER 2500 mg QD 
One dose taken ‘x’ hour after 
last dose 
 
30 Take dose and resume dosing 
36 Take dose and resume dosing 
42 Take dose and resume dosing 
48, missed dose Take dose and resume dosing 
48, two doses Do not double the dose 
Two doses taken ‘x’ h after 
last dose 
 
54 Risk of toxicity, take 1.5 dose 
60 Risk of toxicity, take 1.5 dose 
66 Risk of toxicity, take 1.5 dose 
72, two doses Take doses and resume 
72, one dose Take two doses and resume 
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Table 2.4 Dosing recommendations for DR based on free VPA 
  
 DR 500 mg BID 
One dose taken ‘x’ hour after 
last dose Dosing Recommendation 
15 Take dose and resume dosing 
18 Take dose and resume dosing 
21 Take dose and resume dosing 
24, missed dose Take make-up dose 
24, two doses Take doses and resume dosing
 Two doses taken ‘x’ hour 
after last dose 
 
27 Take doses and resume dosing
30 Take doses and resume dosing
33 Take doses and resume dosing
36 Take doses and resume dosing
DR 1000 mg BID 
One dose taken ‘x’ hour after 
last dose 
 
15 Take dose and resume dosing 
18 Take dose and resume dosing 
21 Take dose and resume dosing 
24, missed dose Take dose and resume dosing 
24, two doses Take doses and resume dosing
Two doses taken ‘x’ hour 
after  
 
27 Take doses and resume dosing
30 Take doses and resume dosing
33 Take doses and resume dosing
36 Take doses and resume dosing
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Figure 2.1 Simulation Scenarios for one missed dose on a once daily regimen. While at 
steady state, next dose was taken 6, 12, 18 hours late and then missed. In the last scenario 
missed dose is replaced. 
 
 
 
 
 
 
 
 
 
 
Scheduled 
dose 
Time 0  6 hours
Delayed dose                                                      one dose 
                                                                          two doses 
 
12 hours 18 hours
Steady State  
24 hours  
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Figure 2.2 Unbound (upper panel) and total (lower panel) VPA concentrations following 
single 1000 mg dose administration of ER (F=0.89) and DR (F=1)
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Figure 2.3 Unbound (upper panel) and total (lower panel) VPA concentrations following 
500 mg bid of DR using average adult parameters. Different missed doses scenarios are 
shown.
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Figure 2.4 Unbound (upper panel) and total (lower panel) VPA concentrations following 
1000 mg QD of ER using average adult parameters. Different missed doses scenarios are 
shown
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A RATIONAL DOSING NOMOGRAM FOR VALPROIC ACID BASED ON 
NONLINEAR PLASMA PROTEIN BINDING 
 
 
 Alaa M. Ahmad, F. Douglas Boudinot, William H. Barr, Ronald C. Reed and William R. 
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             ABSTRACT. Clinicians rely primarily on total valproic acid (VPA) 
concentrations for therapeutic monitoring. However, due to nonlinear plasma protein 
binding of VPA, dose titration is complicated by disproportionality between the total 
drug concentration and dose. The purpose of this report was to develop a nomogram for 
VPA based on total drug concentrations. Nine healthy volunteers were administered 500, 
750 and 1000 mg VPA in a dose escalation study. Plasma protein binding of VPA was 
characterized for each volunteer in vitro. A one-site saturable binding model provided an 
adequate description of the binding of VPA to albumin and yielded (mean, % standard 
error) 2.3 (4.5%) binding sites (N) and an equilibrium association constant (KA) of 6.7 
(17.9%) (L/mM). Predictions for the increase in total concentration observed with dose 
escalation were based on individual and population pharmacokinetic parameters. There 
was close correlation between the predictions based on individual and population 
estimates. Using population estimates, a dosing nomogram for VPA was constructed. To 
minimize the risk of achieving toxic drug concentrations, the dose should not be 
increased more than 2 fold at a time. The nomogram should be used in conjunction with 
patient history and clinical response to aid clinicians in making informed decisions about 
dose-adjustments.  
  
Key words: Valproic acid, protein binding, nomogram, dose titration. 
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Introduction  
            Valproic acid (VPA) is a broad-spectrum antiepileptic drug effective against a 
wide variety of seizure disorders, including complex partial, tonic-clonic convulsive, 
absence and myoclonic seizures. VPA also shows activity against neonatal seizures, 
febrile seizures and status epilepticus [1, 2]. VPA has been used in the treatment of 
bipolar disorders and for the prophylaxis of migraine headaches [3]. The drug is rapidly 
absorbed following oral administration with a bioavailability of greater than 85% [3].  
VPA is metabolized almost entirely by the liver with 30-50 % of the dose appearing in 
urine as glucuronide conjugate and 40% of the dose undergoing mitochondrial β-
oxidation. Less than 15-20 % of the dose is eliminated by other oxidative mechanisms 
and less than 3% of the dose is eliminated as unchanged drug in urine. There is no 
evidence of saturable metabolism. Mean total clearance and steady state volume of 
distribution for total valproate are 0.56 L/h and 11 L, respectively. For free valproate, 
mean unbound clearance and unbound volume of distribution are 4.6 L/h and 92 L, 
respectively. Mean terminal half-life for valproate mono therapy ranged from 9-16 hours 
following oral doses of 250-1000 mg [3].  
 
            VPA binds to plasma proteins in a concentration dependent fashion. As such, the 
free fraction increases from 10% at 40 mg/l to 18.5% at 130 mg/l [3]. The plasma protein 
binding of VPA decreases in the elderly, hepatic and renal impairment and in the 
presence of other medications that have higher binding affinity to the same binding site 
on albumin such as aspirin. This nonlinear binding renders the kinetics of the total drug 
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non-linear such that clearance and volume of distribution of total VPA increase with the 
free fraction. Thus total VPA concentrations increase less than proportionally with dose. 
To date, there is no generally accepted method to titrate the VPA dose based on total 
concentrations. Typically, VPA dosage adjustments are made empirically. This lengthens 
the process by which adequate seizure control and personal therapeutic range for each 
patient is achieved. 
 
            There are several preparations for VPA. Divalproex sodium extended-release 
(Depakote® ER) is a once daily (QD) preparation for VPA. It’s formulated as a 
hydrophilic polymer matrix controlled-release tablet system to provide more consistent 
blood concentrations over 24 hours. This system results in the release of drug in the 
stomach, small intestine, and large intestine over an 18- to 24-hour period of time.  
 
            In this study, two dosing nomograms for VPA were constructed based on plasma 
protein binding data in nine healthy volunteers. A dose escalation study in the same 
volunteers was conducted to test the nomograms. The ER formulation was used in this 
study to provide once-daily dosing for convenience of administration. The nomograms 
can be used for all VPA preparations. 
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Methods  
            This study was approved by the Institutional Review Board of the Virginia 
Commonwealth University Office of Research Subjects Protection and all volunteers 
provided signed informed consent to participate in the study. 
 
Plasma Protein Binding 
            One hundred milliliters (100 ml) of blood were obtained from each volunteer 
prior to the study.  Blood was immediately centrifuged and plasma was obtained and 
stored at -70°C.  Plasma protein binding was characterized for each volunteer separately. 
Briefly, valproic acid (VPA, sodium salt, Sigma-Aldrich, St. Louis, MO) concentrations 
ranging from 25-2000 µg/ml were prepared in plasma and concentrations were confirmed 
by assay. Following incubation at 37°C for one hour, unbound valproic acid was 
separated by ultrafiltration; using a temperature-controlled (37°C) centrifuge (Eppendorf, 
Westbury, NY). Concentrations of VPA were determined using fluorescence polarization 
immunoassay on a TDx analyzer (Abbott Laboratories, Abbott Park, IL) after proper 
dilution. The calibration range for this assay was 12.5-150 µg/ml and 2-25 µg/ml for total 
and free valproate, respectively. Assay variability has been to shown to be less than 5 % 
[4]. Albumin and total protein concentrations were measured for each volunteer as part of 
serum chemistry panel. 
 
            To characterize the relationship between bound and unbound VPA, the change in 
bound VPA concentration after ultrafiltration was adjusted in a manner similar to the 
 
  
 
62
correction for fluid shifts in equilibrium dialysis suggested by Boudinot and Jusko [5]. 
The correction results in a calculated bound fraction before ultrafiltration (FBi) = (DTa - 
DF) * Va /Vi / (DTa - DF) * Va /Vi + DF , where DTa is the total concentration after 
ultrafiltration, DF is the free concentration and Vi  and Va are the volumes of the plasma 
before and after ultrafiltration, respectively. Ultrafiltrate volume was limited to 15% and 
this 0.85 was used as correction factor. Bound VPA (DB) was calculated from DB = DT - 
DF. 
 Three structural models were fitted to the individual plasma protein binding 
curves, a one site saturable binding model, a two site saturable binding model and a two-
site model where one site is saturable and one is not. All modeling was performed using 
WinNonlin (Pharsight Corporation, Mountain View, CA). Models without weighting, 
with 1/Y (observed) or 1/Yhat (predicted) as weights were tried. Models were compared 
based on visual inspection of predicted versus observed plots, precision of parameter 
estimates, residual plots, AIC (Akaike Information Criterion) and SBC (Schwarz 
Bayesian Criterion) for models with similar weighting schemes [6].  
 
            After determination of the structural model, a population model was developed 
using NONMEM (Globomax, Hanover, MD). Additive and exponential error models 
were used to describe the inter-individual variability in the number of binding sites and 
affinity rate constant. Similarly, additive and proportional error models were tried for 
residual variability. Different covariates (continuous and categorical) were tested on both 
N and KA. The change in the objective function (∆obj) was used to judge whether a 
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N and KA. The change in the objective function (∆obj) was used to judge whether a 
covariate has a significant effect on the fit. It is assumed that ∆obj is approximately χ2 
distributed and thus a reduction in the objective function of 3.84 units corresponds to a 
significance level of 0.05. The precision of parameter estimates with different methods of 
estimation (first order, first order conditional estimation with and without interaction) 
was compared and the method that provided best precision was used for estimation. Final 
model selection was based on the change in objective function for nested models, 
goodness of fit and residual plots and precision of parameter estimates for fixed and 
random effects [7]. 
 
Dose Escalation Study 
            Nine healthy volunteers were administered increasing doses of Depakote® 
extended release (ER) formulation. As shown in figure 3.1, during the first week, 500 mg 
of the ER formulation was taken once a day (QD). During the second week, the dose was 
increased to 750 mg QD and in the third week the dose was increased to 1000 mg QD. 
Two trough plasma samples were collected after steady state was reached at each dose.  
 
Nomogram  
            The nomogram aims to quantify the nonlinear relationship between total VPA 
concentration and the dose assuming that unbound VPA is proportional to the dose. 
Using individual protein binding estimates, simulations were performed for each 
volunteer to predict the increase in dose needed to achieve the increase in total 
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concentration observed with dose escalation. Following this, predictions were based on 
the population model and compared to the predictions from individual estimates. All 
simulations were based on a one site saturable binding model, DB = (N * KA * DF * P) / 
(1 + KA * DF), where P is the albumin concentration, N is the number of binding sites and 
KA is the equilibrium association constant. The population estimates were used to 
construct the nomograms. 
 
Results 
Plasma Protein Binding  
            A one site saturable binding model provided the best fit to the plasma protein 
binding data for each of the volunteers. Figure 3.2 shows a plot of fraction bound as a  
function of total VPA concentration for all volunteers. A weighting factor of 1/Yhat 
provided parameter estimates with best precision. Figure 3.3 shows a simulation for 
bound VPA as a function of unbound VPA concentrations using parameters obtained 
through modeling.   
 
            A one-site saturable binding model was used as a structural model for population 
model development. Due to the relatively small sample size, two random effects 
simultaneously on N and K introduced either additively or exponentially could not be 
estimated with good precision. From evaluation of the individual estimates, a random 
effect on K only that was estimated with reasonable precision (~ 31.0%) was retained. 
Thus, K was allowed to vary across volunteers while N was fixed. An exponential inter-
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individual variability model was superior to the additive model in terms of precision of 
the random effect estimated and thus was retained. Residual variability was introduced 
using an additive and a proportional error model. The latter was used in the final model 
since there was an increase with variability indicated by residual plots with higher 
concentrations. The first order conditional estimation (FOCE) method provided superior 
estimates in terms of parameter precision compared to the first order method and the 
interaction option didn’t provide further improvement and thus was not used.  
 
            Following this, different covariates including age, weight, body mass index, 
albumin and total protein concentrations and gender were introduced on both N and K 
and found insignificant (∆obj < 3.84), which is not surprising since the sample size is 
small.  
 
            The final population model predicted (mean, %standard error or %SE) an N of 2.3 
(4.5%) and KA of 6.7 (17.9%) (L/mM). The inter-individual variability term for KA 
(ETA, exponential error model) was estimated to be 30.7% (%SE= 30.9%) and residual 
variability (proportional error model) was estimated to be 31.9% (%SE=14.8%). The 
FOCE method was used. The model didn’t include any covariates. The fitted line in 
figure 2 represents final population model estimates.  
 
The VPA Nomogram 
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            Predictions were performed at the first dose increase (500 to 750 mg, 50% 
increase in dose), second dose increase (750 to 1000 mg, 33% increase in dose) and also 
from 500 to 1000 mg (100% increase in dose). Thus, for each volunteer, individual 
binding parameters were used to predict the needed increase in dose for each combination 
of trough levels. These individual predictions are summarized in table 3.1 and differences 
between the individual predictions and nominal percent increase in dose are illustrated in 
figure 3.4. Exact predictions have a difference of zero. Similarly, predictions based on 
population binding parameters were performed for each combination of trough levels for 
each volunteer and are shown in table 3.2. The differences between the population 
predictions and nominal percent increase in dose are depicted in figure 3.5. 
 
            To compare individual and population predictions, two performance measures for 
numeric prediction, root mean squared error (RMSE) and mean absolute error (MAE) 
were calculated at each dose increase (50%, 33% and 100%). These values are 
summarized in table 3.3. RMSE and MAE for individual and population predictions were 
not statistically significantly different (one tailed t-test, P >0.3).   
 
            Using population estimates, a nomogram for VPA was developed. For purposes 
of illustration, the nomogram was divided into two dose-titration charts. The first chart 
shows dose titration at total concentrations between 20-100 µg/ml (Table 3.4) and the 
second chart acilitates dose-titration at total concentrations between 100-200 µg/ml 
(Table 3.5). One volunteer experienced increased gastrointestinal motility that resulted in 
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mal absorption of the compound, and therefore predictions were not performed for this 
volunteer. 
 
Discussion 
            There are different techniques to measure unbound drug concentrations. In this 
study, ultrafiltration was used to separate unbound VPA. Ultrafiltration has been used and 
continues to be used increasingly because it simple, fast and efficient. Since there are 
concerns that the drug might be lost to the ultrafiltrate leading to a change in total 
concentration, it’s been suggested to average total concentrations measured before and 
after ultrafiltration [8]. One other issue with the use of ultrafiltration is the change in 
protein concentration as plasma water is filtered. It has been suggested to limit the 
volume of the ultrafiltrate to 10-15% of initial plasma volume [8] to avoid considerable 
changes in protein concentration that might affect the binding. Thus, a correction for the 
change in bound concentration due to the change in protein concentration during 
ultrafiltration was developed. With this correction the calculated bound concentration 
takes into account the increase in protein concentration. In that sense, this correction is a 
more reasonable representation of the bound fraction that is not simply an average of pre 
and post ultrafiltration measurements. 
 
            Plasma protein binding of VPA has been reported previously. Yu [9] reported 
plasma protein binding parameters for VPA at steady state in children with epilepsy and  
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also in pooled sera of 10 healthy volunteers. One class of binding sites was detected both 
in vitro and in vivo. In vitro, N was 1.86 and KA was 8.03 L/mmol while in vivo studies 
yielded N and KA values of 2.48 and 4.98 L/mmol, respectively. Parameters obtained in 
vitro were not statistically significantly different from those generated in vitro. Cramer et 
al [10] studied the protein binding of VPA in patients with epilepsy on mono- and poly-
therapy with valproate. The authors didn’t estimate binding parameters but concluded 
that free valproate is more informative for therapeutic monitoring. In a later in vivo study 
with 37 patients the same group reported a binding site concentration (N*P) of 1.17 
mmol/L and KA of 10.99 L/mmol for mono therapy patients and N*P of 1.04 mmol/L and 
KA of 13.3 L/mmol for mono and poly therapy patients combined [11].  The authors 
could not detect more than one saturable site but suggested the presence of a second non-
saturable site. Another group [12] also reported in vivo estimates in nine healthy 
volunteers, where they suggested the presence of one saturable site (N =1 .80) with a KA 
value of 23.10 L/mmol. Most of the authors studied the binding of VPA at concentrations 
close to the therapeutic range (~ 40-200 µg/ml).  
 
             A recent paper [13] reported two saturable sites for valproic acid following rapid 
infusions in patients with epilepsy. Parameter estimates were N1=1.54, K1= 11.9 L/mmol 
and N2=0.19, K2=164 L/mmol. The affinity constant for the second site was not well 
estimated and there wasn’t sufficient evidence to conclude that a second high affinity, 
low capacity binding site actually exists. One group [14] investigated the binding of VPA 
over a range of (0.56-2016) µg/ml using equilibrium dialysis, ultrafiltration and  
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ultracentrifugation reported the presence of two saturable sites, both estimated with good 
precision. However, there were discrepancies in the binding constants for the second 
class across methods.  
 
            In the present study, parameter estimates for a one saturable site model compare 
well with parameters values reported in the literature. A second binding site that might be 
operational at concentrations below the limit of detection of the assay (12.5 µg/ml) 
cannot be ruled out. However, if a second site does exist it has no clinical relevance since 
it is saturated at concentrations lower than therapeutic and probably represents binding to 
a protein other than albumin.  
 
            Nomograms can be designed to predict a prognostic outcome [15], calculate doses 
[16], derive useful clinical biomarkers [17] and predict disease progress [18]. VPA is 
widely used in neuropsychiatric disorders [3] and it’s critical to maintain drug 
concentrations in the therapeutic range. Total and unbound VPA plasma concentrations 
can be determined using fluorescence polarization immunoassay on the TDx/TDx FLx 
system. The unbound drug, in theory, is better correlated with the pharmacological effect 
than the total drug. Despite this, clinicians primarily rely on total VPA concentrations to 
individualize therapy. In epilepsy, most patients will respond to total concentrations 
between 50-150 µg/ml [1].  
 
 
  
 
70
            There are no reports in the literature that describe dose escalation studies for VPA 
with timed measurements. Such information is needed to test whether plasma protein 
binding can adequately account for the non-linear relationship between total 
concentrations and the dose. To obtain this information, we conducted a dose escalation 
study in nine healthy volunteers. This information coupled with plasma protein binding 
data was used to develop the VPA nomogram. Table 3.1 summarizes predictions for dose 
increase using individual plasma protein binding parameter estimates. There were 
considerable inter- and intra-individual variabilities apparent in the trough concentrations 
to which these discrepancies can be attributed. There are several reports on the population 
kinetics of VPA that attempt to quantify and explain this variability [19-21].  
 
            The second set of predictions, summarized in table 3.2, use population estimates. 
The purpose of performing similar predictions with population estimates was to assess 
whether the predictions from these estimates are reasonably close to the predictions based 
on individual parameters. Since there were no significant differences between individual 
and population predictions (based on RMSE and MAE); a dosing nomogram using 
population estimates was developed. The nomogram can also be used to decrease the 
dose if there is a need to lower the total concentration.  
 
            Since there is a risk of over predicting the needed increase in dose, it is not 
recommend increasing the dose by more than 2 fold at a time. The nomogram should be 
used in conjunction with patient history and clinical response. If there is information on 
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the expected concentrations in a certain patient with dose increase, this information 
should supplement the predictions provided by the nomogram. It should be noted that the 
nomograms could be used for all VPA preparations and regardless of whether patients are 
on enzyme-inducing or –inhibiting co-medication. The nomogram will always predict a 
percentage of the previously administered dose and not an absolute value. 
 
            In summary, two dosing charts for valproic acid were introduced to facilitate 
rational dose titration based on total concentrations. This will aid clinicians in 
maintaining VPA concentrations in the desired range and minimize the guessing involved 
in dose titration. The nomograms can be used for all VPA preparations.  
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Appendix 
Correction of Bound VPA Concentrations After Ultrafiltration 
In order to characterize the relationship between bound and unbound VPA, a new method 
that adjusts for the change in bound VPA concentration after ultrafiltration was used. 
During ultrafiltration, plasma water passes through the membrane carrying the free drug. 
This leads to an increase in protein concentration. In a manner similar to the correction 
for fluid shifts in equilibrium dialysis suggested by Boudinot and Jusko [3], the change in 
bound drug concentration after ultrafiltration can be derived as follows: 
Initial amount of protein (APi) = Amount of protein after ultrafiltration (APa)     
Thus; 
Vi * Pi = Va * Pa                                                                   Eq. 1 
assuming no loss of protein through the filter, where Vi and Va are the initial plasma and 
retentate volumes, and Pi and Pa are the initial and post ultrafiltration protein 
concentrations, respectively. It follows then that 
Pa = Pi * Vi /Va                                                                        Eq. 2 
If there are no volume shifts, the bound concentration (DBi ) generally can be described 
by (where n is the number of binding sites): 
DBi = ∑
=
n
m 1
(N * K * Pi * DF)/ (1 + K * DF)                           Eq. 3 
Where N and K are the number of binding sites and affinity constant, respectively, and DF 
is the free drug concentration. After ultrafiltration and with substituting Pa from Eq. 2 the 
bound concentration (DBa) can be written as:  
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DBa = ∑
=
n
m 1
 (N * K* [Pi * Vi /Va] * DF) / (1 + K * DF)                    Eq. 4  
Assuming that N and K do not vary with changes in protein concentration  P, then: 
DBa * Va /Vi = ∑
=
n
m 1
 (N * K* Pi * DF)/ (1 + K * DF) = DBi              Eq. 5 
To calculate the fraction of bound drug before ultrafiltration (FBi) one can use: 
FBi = DBi / (DBi + DF)  
Substituting for DBi from Eq. 5, it follows that: 
FBi =(DBa * Va /Vi ) / (DBa * Va /Vi + DF)                              Eq. 6  
Since total drug concentration after ultrafiltration (DTa) as well as DF are determined 
experimentally, then: 
FBi = (DTa - DF) * Va /Vi / (DTa - DF) * Va /Vi + DF                 Eq. 7 
This calculated bound fraction value was used for modeling.  
 
 
 
 
 
 
 
 
 
 
  
 
76
Table 3.1 Predictions for percent increase in dose based on individual estimates. 
Vol
Ctot from-to Pred Ctot from-to Pred Ctot from-to Pred
1 41-55 41% 55-67 27% 41-67 79%
43-55 32% 55-64 20% 41-64 69%
43-67 68%
43-64 59%
2 25-50 130% 38-51 40% 25-51 134%
25-38 67% 38-56 58% 25-56 163%
27-50 107% 50-56 15% 27-51 110%
27-38 50%  27-56 137%
3 28-31 9% 31-55 94% 28-55 111%
28-32 16% 31-73 173% 28-73 197%
22-31 42% 32-55 82% 22-55 175%
22-32 51% 32-73 156% 22-73 287%
4 30-49 73% 49-70 53% 30-70 165%
30-55 99% 49-76 70% 30-76 194%
34-49 51% 55-70 33% 34-70 131%
34-55 74% 55-76 48% 34-76 156%
5 26-40 62% 40-50 30% 26-33 29%
26-38 53% 38-50 38% 26-50 111%
6 45-56 32% 56-76 49% 45-76 95%
45-57 35% 56-69 31% 45-69 72%
39-56 55% 57-76 45% 39-76 130%
39-57 59% 57-69 28% 39-69 103%
7 57-85 79% 85-89 7% 57-89 92%
57-80 62% 80-89 18% 57-79 62%
54-85 92% 54-89 106%
54-80 74% 54-79 74%
8 27-52 107% 52-59 16% 27-59 140%
27-46 81% 52-61 21% 27-61 150%
29-52 93% 46-59 33% 29-59 125%
29-46 68% 46-61 38% 29-61 133%
 
 500-750 750-1000 500-1000
(50% increase in dose) (33% increase in dose) (100 % increase in dose)
DOSE INCREASE
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Table 3.2 Predictions for percent increase in dose based on population estimates.  
Vol
Ctot from-to Pred Ctot from-to Pred Ctot from-to Pred
1 41-55 45% 55-67 29% 41-67 87%
43-55 37% 55-64 21% 41-64 75%
43-67 77%
43-64 66%
2 25-50 126% 38-51 43% 25-51 131%
25-38 62% 38-56 62% 25-56 161%
27-50 105% 50-56 16% 27-51 109%
27-38 46% 27-56 137%
3 28-31 14% 31-55 100% 28-55 127%
28-32 18% 31-73 190% 28-73 229%
22-31 47% 32-55 93% 22-55 194%
22-32 53% 32-73 179% 22-73 326%
4 30-49 79% 49-70 59% 30-70 185%
30-55 108% 49-76 78% 30-76 218%
34-49 54% 55-70 37% 34-70 145%
34-55 79% 55-76 53% 34-76 173%
5 26-40 64% 40-50 32% 26-33 32%
26-38 54% 38-50 40% 26-50 115%
6 45-56 31% 56-76 50% 45-76 96%
45-57 33% 56-69 31% 45-69 72%
39-56 57% 57-76 47% 39-76 135%
39-57 60% 57-69 29% 39-69 106%
7 57-85 73% 85-89 7% 57-89 86%
57-80 59% 80-89 17% 57-79 56%
54-85 86% 54-89 102%
54-80 70% 54-79 67%
8 27-52 116% 52-59 17% 27-59 153%
27-46 86% 52-61 23% 27-61 165%
29-52 102% 46-59 36% 29-59 137%
29-46 74% 46-61 43% 29-61 148%
DOSE INCREASE
(50% increase in dose) (33% increase in dose) (100 % increase in dose)
750-1000 500-1000 500-750 
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Table 3.3 Root mean squared errors (RMSEs) and mean absolute errors (MAEs) for 
individual and population predictions 
 
 Individual Population 
Dose increase RMSE MAE RMSE MAE 
50% 0.31 0.24 0.32 0.25 
33% 0.44 0.26 0.51 0.30 
100% 0.56 0.42 0.67 0.49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
79
Table 3.4 Dosing nomogram for total VPA concentrations between 20-100 mg/l. 
25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100
20 26 55 87 116 152 184 223 258 300 342 388 433 484 533 588 646
25 21 23 49 72 100 125 156 184 218 251 287 323 364 402 446 492
30 35 19 21 39 62 83 108 131 158 185 214 243 277 308 343 381
35 47 33 17 15 34 52 72 91 114 136 160 184 212 238 267 298
40 54 42 28 13 17 31 49 66 85 105 126 146 170 193 218 245
45 60 50 39 26 14 13 28 42 59 76 93 111 132 151 173 196
50 65 56 45 34 24 11 14 26 41 56 71 87 106 123 142 162
55 69 61 52 42 33 22 12 11 24 37 51 65 81 96 113 131
60 72 65 57 48 40 30 21 10 12 23 36 49 63 77 92 108
65 75 69 61 53 46 37 29 19 11 10 22 33 46 58 72 86
70 77 72 65 58 51 43 36 27 19 9 10 20 32 43 56 69
75 79 74 68 62 56 48 42 34 26 18 9 9 20 30 41 53
80 81 76 71 65 59 53 47 39 33 25 17 8 10 19 29 40
85 83 78 73 68 63 57 51 45 39 31 24 17 9 8 18 28
90 84 80 76 70 66 60 55 49 43 37 30 23 16 8 9 18
95 85 82 77 73 69 63 59 53 48 42 36 29 23 15 8 8
100 87 83 79 75 71 66 62 57 52 46 41 35 29 22 15 8
95 90 85 80 75 70 65 60 55 50 45 40 35 30 25 20
Titration up
Titration down  
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Table 3.5 Dosing nomogram for total VPA concentrations between 100-200 mg/l. 
105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200
100 8 16 26 35 45 55 66 77 89 101 115 128 142 157 172 188 205 222 240 258
105 8 8 16 24 34 43 53 64 75 86 98 111 124 138 152 166 182 198 214 231
110 14 7 8 16 24 33 42 52 62 73 84 96 108 121 134 148 162 177 192 207
115 20 14 7 7 15 23 32 41 51 60 71 82 93 105 117 130 143 157 171 185
120 26 20 13 7 7 15 23 32 41 50 59 69 80 91 102 114 126 139 152 166
125 31 25 19 13 7 7 15 22 31 39 48 58 68 78 88 99 111 123 135 148
130 35 30 25 19 13 7 7 14 22 30 39 47 56 66 76 86 97 108 119 131
135 40 35 30 24 19 13 7 7 14 21 29 38 46 55 64 74 84 94 105 116
140 44 39 34 29 24 18 12 6 7 14 21 29 37 45 54 63 72 82 92 102
145 47 43 38 34 29 24 18 12 6 6 14 21 28 36 44 52 61 70 80 89
150 50 46 42 38 33 28 23 18 12 6 7 13 20 28 35 43 51 60 69 78
155 53 50 46 42 37 33 28 23 18 12 6 6 13 20 27 34 42 50 58 67
160 56 53 49 45 41 37 32 27 22 17 12 6 6 13 19 26 34 41 49 57
165 59 55 52 48 44 40 36 32 27 22 17 11 6 6 12 19 26 33 40 48
170 61 58 55 51 48 44 40 36 31 26 22 17 11 6 6 12 19 25 32 39
175 63 60 57 54 51 47 43 39 35 31 26 21 16 11 6 6 12 18 25 31
180 65 62 60 56 53 50 46 42 39 34 30 26 21 16 11 6 6 12 18 24
185 67 64 62 59 56 53 49 46 42 38 34 30 25 20 16 11 5 6 12 17
190 69 66 64 61 58 55 52 49 45 41 38 33 29 25 20 15 10 5 6 11
195 71 68 66 63 60 57 54 51 48 44 41 37 33 29 24 20 15 10 5 5
200 72 70 67 65 62 60 57 54 51 47 44 40 36 32 28 24 19 15 10 5
195 190 185 180 175 170 165 160 155 150 145 140 135 130 125 120 115 110 105 100
Titration up
Titration down
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Table 3.6 Individual plasma protein binding parameter estimates for a one saturable site 
model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Volunteer N 
Mean (SE) 
K (L/mM) 
Mean (SE) 
001 2.5 (10.9%) 3.4 (31.2%) 
002 2.4 (9.7%) 9.1 (36.2%) 
003 3.3 (8.3%) 4.5 (24.6%) 
004 3.1 (10.6%)  3.7 (31.1%) 
005 2.5 (8.3%) 5.6 (23.4%) 
006 2.6 (6.4%) 5.5 (19.3%) 
007 2.2 (12.9%) 7.4 (41.3%) 
008 2.6 (9.2%) 3.0 (23.8%) 
009 2.0 (5.3%) 8.8 (15.5%) 
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Table 3.8 Volunteers demographics. 
 
 
Vol Age (Y) Weight (lb) Height (in) Race Gender
1 31 126 65.5 C F
2 34 150 68.5 C F
3 31 184 71.0 AA M
4 35 186 71.0 AA M
5 49 173 69.0 C M
6 29 204 70.0 AA F
7 38 175 65.0 AA F
8 47 182 66.5 C M
9 31 145 66.0 H M  
 
         C: Caucasian, AA: African American, H: Hispanic 
         F: female, M: Male  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
84
Table 3.9 Concomitant medication and adverse events (AE) at study conclusion. 
 
 
Vol. # Concomitant medications AE
1 Tylenol, Immodium, Depo-Provera, Unisom Runny nose
2 Ponstel, Yasmin Hematoma from Stick
Rash, Dizziness, Headache
3 NONE NONE
4 Alka-seltzer, Tylenol PM Sore throat, cough
5 NONE NONE
6 Orthotri-Cyclen, Nyquill Sleepeliness, drowsiness
Breakthrough bleeding
7 NONE Diarrhea, Stomach Cramps
8 NONE NONE
9 NONE Diarrhea  
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Figure 3.1 Dose escalation Schematic. 
 
 
Period 1 
500 mg QD
7 days  
Study days 1-7 
Period 2 
750 mg QD
7 days  
Study days 8-14 
Period 3 
1000 mg 
7 days  
Study days 15-21 
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Figure 3.2 Fraction bound as a function of total VPA concentrations (mcg/ml) for nine 
volunteers. The fitted line represents the population fit in NONMEM. 
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Figure 3.3 Simulations of bound versus unbound VPA concentrations (mcg/ml) for nine 
volunteers using parameters obtained from a one site saturable binding model. 
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Figure 3.4 Difference between individual predictions and nominal increases in dose. 
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Figure 3.5 Difference between population model predictions and percent increases in 
dose.
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THE EFFECT OF DELAYED/MISSED DOSES ON VALPROIC ACID 
CONCENTRATIONS FOLLOWING DEPAKOTE® EXTENDED RELEASE 
 
 
 
 
Alaa M. Ahmad, F. Douglas Boudinot, William H. Barr, Ronald C. Reed and William R. 
Garnett  
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ABSTRACT  
            Nine healthy volunteers were administered 500, 750 and 1000 mg Depakote® ER 
in a dose escalation study. After steady state at 1000 mg dose was reached, volunteers 
were randomized into three groups each subjected to a different delayed dose scenario. 
Groups one and two took a delayed dose (1000 mg) 6 h and 12 h respectively after the 
last scheduled dose. Group three took a daily dose plus replacement dose (2000 mg) 24 h 
after the last scheduled dose. Plasma protein binding of valproic acid (VPA) was 
characterized for each volunteer in vitro. Population pharmacokinetics models were 
developed for unbound VPA concentrations and for plasma protein binding. The 
combined information was used to construct a model to simulate missed dose scenarios 
for 100 subjects. The simulation model accounted for the effect of missed doses in the 
study volunteers and can be used to make dosing recommendations when patients miss a 
scheduled administration. At the higher dose of 2000 mg, the release from the ER 
preparation was not extended for 22 h. Although dose dumping has not been reported to 
date with Depakote® ER, it is not recommended to take more than two tablets (1000 mg) 
at once. A make-up dose can be taken 12 h after the daily dose if a dose is missed from a 
1000 mg ER regimen. 
 
Key words: valproic acid, missed doses, simulation, variability. 
 
 
 
  
  
92
Introduction  
            Valproic acid (VPA) is a broad-spectrum antiepileptic drug effective against a 
wide variety of seizure disorders, including complex partial, tonic-clonic convulsive, 
absence and myoclonic seizures [1, 2]. VPA has been used in the treatment of bipolar 
disorders and for the prophylaxis of migraine headaches. Other uses include management 
of acute mania, anxiety disorders and posttraumatic stress disorder. The drug has a good 
safety profile and most side effects are mild and transient. Two serious side effects are 
rare but fatal hepatotoxicity and teratogenicity [3]. 
 
            There are several preparations for VPA. Divalproex sodium extended-release 
(Depakote® ER) is a once daily (QD) preparation for VPA. It’s formulated as a 
hydrophilic polymer matrix controlled-release tablet system to provide more consistent 
blood concentrations over 24 hours. This system results in the release of drug in the 
stomach, small intestine, and large intestine over an 18- to 24-hour period of time.  
 
            The ER preparation was developed to provide convenient QD dosing and reduce 
side effects (mostly gastro-intestinal) associated with faster release preparations. Since 
VPA is used widely in different neuropsychiatric disorders, there are concerns about the 
effect of a missed or delayed dose from a once-daily regimen. We addressed this issue 
systematically in a previous paper using simulations [4].   
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            As a follow-up for the previous simulations, a study was conducted in nine 
healthy volunteers. The objective of this study was to explore the effect of 
delayed/missed doses on steady state concentrations following the administration of 
Depakote® (ER) formulation and to validate the simulation model that accounts for 
delayed/missed doses.  
 
Methods  
            The Institutional Review Board of the Virginia Commonwealth University Office 
of Research Subjects Protection approved this study, and all volunteers provided signed 
informed consent prior to participation.    
 
 
Clinical Study 
            Nine healthy volunteers were administered 500, 750 and 1000 mg VPA in a dose 
escalation study. Two trough plasma samples were collected after steady state was 
reached at each dose. On day 22 of the study, all volunteers were expected to be at steady 
state concentrations at a 1000 mg QD of the ER formulation. Volunteers were pre 
randomized, group one took their next scheduled dose 6 hours late, group two took their 
next dose 12 hours late; while group three missed their dose completely on day 22 (figure 
4.1). On day 23 of the study, groups one and two took 1000 mg, while group three took 
the daily dose plus replacement dose (2000 mg). All volunteers took 1000 mg on day 24. 
Drug administration was then reduced gradually over the course of four days to safely 
remove volunteers from the valproic acid regimen. Serial blood sampling was performed   
  
  
94
for 24 hours around the delayed dose and plasma was stored at -70 °C till analysis. Prior 
to analysis, an aliquot of each plasma sample was incubated at 37 °C for one hour and 
unbound valproic acid was separated by ultrafiltration using a temperature-controlled (37 
°C) centrifuge (Eppendorf, Westbury, NY). Free and total valproic acid concentrations 
were determined using fluorescence polarization immunoassay; on a TDx analyzer 
(Abbott Laboratories, Abbott Park, IL). The calibration range for this assay was 12.5-150 
µg/ml and 2-25 µg/ml for total and free valproate, respectively. Assay variability has 
been to shown to be less than 5 % [5].  
 
Population Model Development  
            The purpose of this analysis was to obtain estimates for clearance (CL/F) and 
volume of distribution (Vd/F) and their inter- and intra-individual variabilities using 
NONMEM (Globomax, Hanover, MD). A one compartment model was used as a 
structural model. Inter-individual variabilities in CL/F and Vd/F (ηCL and ηVd ) were 
modeled as normally distributed parameters with a mean of zero and variances ω2CL and  
ω2Vd, respectively, using exponential error models. Residual variability was modeled 
using a proportional error model as a normally distributed parameter with mean of zero 
and variance σ2. The first order conditional estimation method with interaction was used 
for estimation [6].   
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            Covariates were incorporated using linear models. The change in the objective 
function (∆obj) was used to judge whether a covariate explains some of the random 
variability in CL or Vd. It is assumed that ∆obj is approximately χ2 distributed and thus a 
reduction in the objective function of 3.84 units corresponds to a significance level of 
0.05 [6]. Final model selection was based on the change in objective function for nested 
models, goodness of fit and residual plots and precision of parameter estimates for fixed 
and random effects.  
 
Simulations 
            Once estimates for CL/F, Vd/F and their intra- and inter-individual variabilities 
were obtained, a simulation model was constructed in the Trial Simulator TM (Pharsight 
Corporation, Mountain View, CA). The model assumed that the kinetics of unbound 
VPA were linear and thus started with unbound parameters. Total VPA concentrations 
were simulated using a plasma protein binding model. Development of the plasma 
protein binding model for VPA was based on data from the same nine volunteers and is 
reported elsewhere [7]. A one site saturable binding model was used that incorporates 
inter-individual variability in the equilibrium association constant KA. Unbound VPA 
concentrations (Cu) were simulated according to Cu= F*D/CLu*T (eCLu/Vu *T –1) e– CLu/Vu t, 
where D is the dose, Vu is the volume of distribution of unbound drug, CLu is the 
systemic clearance of unbound drug, F is bioavailability and T is the duration of the zero 
order input [8]. T was fixed to 22 h and F to 0.89 [9].Total VPA concentrations (Ct) was  
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calculated using Ct= Cu + (N KCuP)/(1+KCu) Where P is albumin concentration, N and 
KA are the number of binding sites and equilibrium association constant, respectively.  
 
            The simulation model was used to simulate the delayed doses scenarios in the 
clinical study. Unbound and total VPA steady state concentrations following multiple 
doses of 1000 mg daily of ER were generated for 100 hypothetical subjects. 
Concentration time profiles were generated for delaying the dose by 6 h (group1), 12 h 
(group 2) and 24 h (group3). In the third scenario (24 late, missed dose), a replacement 
dose was given (dose double-up).  
 
Results 
Clinical Study 
            All volunteers completed the study. One volunteer experienced increased 
gastrointestinal motility that resulted in mal absorption of the compound, and thus 
concentration decreased with dose escalation. The data for this volunteer were excluded 
from population model development.  
 
Population model  
            Dosing, concentration-time data and covariates (age, weight, body mass index and 
gender) for eight volunteers were used for analysis (24 days). None of the covariates 
tested resulted in a significant reduction in the objective function from the base model 
and thus the final model included no covariates. The final model estimated a CL/F of 5.4 
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 (0.05%) L/h and a Vd/F of 186 L (0.1%). The inter-individual variabilities in CL/F and 
Vd/F were 25.6% and 15.9% respectively. The residual variability was estimated to be 
23.4%.  
 
            Estimates for plasma protein binding parameters obtained previously [7] were N = 
2.3 (4.5%) and KA = 6.7 (17.9%) (L/mM). The inter-individual variability term for KA 
(ηK, exponential error model) was estimated to be 30.7% and residual variability 
(proportional error model) was estimated to be 31.9%.  
 
Simulation Study 
            The simulation model is shown in figure 4.2. Parameter means and their 
variabilities were obtained from this study and the previous analysis of plasma protein 
binding data [7]. 
 
            Figures 4.3-4.5 show results for simulation of 100 individuals under different 
scenarios. Results for the three groups in this study are superimposed on the 
corresponding scenario. Figure 4.3 shows total and unbound concentrations, respectively, 
for group one which took a dose 6 hours after the scheduled dose. Figure 4.4 shows total 
and unbound concentrations for group two which took a dose 12 hours after the 
scheduled dose. Results for group three (missed dose followed by replacement dose) are 
shown in figure 4.5 for total and unbound concentrations. For group three, it seems that 
the release of VPA from the ER formulation was not extended for 24 hours at this higher 
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dose. Also volunteer 007 (group 1) appeared to have a higher free concentration that 
what’s expected. This couldn’t be attributed to medical history or disease state. Plasma 
protein binding curve for 007 was not significantly different from other volunteers.  
 
Discussion  
            Previously, a systematic characterization of the effect of missed doses following 
the administration of Depakote® ER using simulations was performed [4]. The 
simulations suggested that at a daily dose of 1000 mg, a delayed or missed dose should 
be replaced as soon as possible with no risk of toxicity in the case of dose double-up. The 
previous simulation model did not include estimates for residual variability and estimates 
for random variability in system parameters were obtained from the literature. In this 
study, we were able to obtain estimates for clearance and volume of distribution of 
unbound VPA and their inter-individual variabilities. An estimate for residual variability 
accounting for model misspecification, measurement error and intra-individual variability 
was also obtained and incorporated into the current simulation model. Further in the 
previous simulation model estimates for plasma protein binding parameters and their 
variabilities were not obtained in the same population as CL and Vd of the unbound drug. 
In this study, plasma protein binding was characterized in vitro for each volunteer and 
estimates for plasma protein binding parameters and the inter-individual variability in the 
equilibrium binding association constant were obtained. An estimate for the residual 
variability in plasma protein binding curves was used in the current simulation model. 
With this, possible sources of the variability in the study population  
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were accounted for. Unfortunately, due to the small sample size, covariate trends could 
not be detected. Therefore, the simulation model didn’t include any covariates.  
 
            The simulation model developed in this study accounts for the effect of delayed 
doses in the three groups for both unbound and bound VPA. The previous model didn’t 
completely account for all individuals (results not shown) because it lacked specification 
of residual variabilities.  
 
            It is apparent from the results of this study that the ER preparation does not 
always provide extended release over 22 hours. Although the release rate was fixed to 22 
hours in the simulation model, the population model estimated ~ 43% inter-subject 
variability in the duration parameter. Most of this variability is contributed by group 
three, for whom the release was extended to 12 hours at best and much less for volunteer 
one. There is no reason to believe that the release from the ER preparation should differ 
at higher doses [10], apart from the increase surface area, which might not totally account 
for the enhanced release. To ensure patient safety, taking four ER tablets (2000 mg) at 
once is not recommended. Patients are advised to take 1000 mg and then another 1000 
mg after 12 hours if a dose is completely missed from a 1000 mg QD ER regimen. A 
dose taken 6 or 12 h late from a once-daily ER regimen should be replaced as soon as 
remembered. 
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            In summary, a simulation model that appropriately incorporates information on 
the inter-subject variabilities in unbound and bound VPA and their residual variabilities 
was developed and validated in healthy volunteers. This model can be used to derive 
dosing recommendations in the case of delayed/missed doses. 
 
Comparison between original and revised models 
            Table 4.1 lists parameters estimates and their standard deviations used in original 
and revised simulations models. Clearance estimates are comparable in both models 
while volume of distribution is almost double in revised model. A different plasma 
protein binding model was used in each model; the original model employed a two-site 
saturable binding model. It can be seen that the affinity rate constant (K2) is not estimated 
with good precision (COV=80%). The revised model employed a one-site saturable 
binding model and parameters were well estimated. During the process the identifying 
the structural model (that lead to the revised one-site model), a two site model was tested 
but parameters were not estimated with good precision and convergence couldn’t be 
achieved for several volunteers. Being the case, a one-site model was used in the revised 
simulation model to account for PPB of VPA to albumin. Albumin concentrations were 
similar in both models.    
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Table 4.1 Parameters for original and revised simulation models. 
 
Parameter 
(SD) 
Original model Revised model 
CLu (L/h) 5.04 ±1.00  5.4 ± 0.0027  
Vdu (L) 95.1 ± 19.0  186 ± 0.186 
N1  1.54 ± 0.108 N= 2.3 ± 0.1 
K1 (L/mmol) 11.9 ± 1.99 K= 6.7 ± 1.2 
N2 0.194 ± 0.0783 - 
K2 (L/mmol) 164 ± 141  - 
P (mmol/L) 0.528 ± 0.0528 0.57 ± 0.06 
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Figure 4.3 Simulated total (upper panel) and free (lower panel) VPA concentrations for 
100 subjects when a 1000 mg is taken 6 h late. Results for group one are superimposed 
(subjects 005, 007, 008).  
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Figure 4.4 Simulated total (upper panel) and free (lower panel) VPA concentrations for 
100 subjects when a 1000 mg is taken 12 h late. Results for group two are superimposed 
(subjects 002, 003, 004).  
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Figure 4.5 Simulated total (upper panel) and free (lower panel) VPA concentrations for 
100 subjects when a 1000 mg is missed followed by dose double-up. Results for group 
three are superimposed (subjects 001, 006, 009). 
Dose
Dose
  
  
108
 
 
 
CONCLUSIONS  
 
            Using Monte Carlo simulations, the effect of different patterns of poor 
compliance on ER QD and DR BID were systematically characterized. Non-linear 
binding of VPA to albumin was incorporated into the model, and the results were based 
on total and unbound VPA for comparison. The effect of poor compliance is less 
significant on DR BID compared to ER QD. Dosing recommendations in the case of a 
missed or delayed dose are both formulation and dose dependent. Since total VPA 
concentrations show higher inter-individual variability and tend to under-estimate the 
effect of poor compliance; the use of unbound VPA concentrations may offer an 
advantage in therapeutic monitoring.  
 
            The VPA nomogram is based on non-linear plasma protein binding data and 
quantitates the non-linear relationship between total concentrations and the dose. To   
minimize the risk of achieving toxic drug concentrations, the dose should not be 
increased more than 2 fold at a time. The nomogram should be used in conjunction with 
patient history and clinical response to aid clinicians in making informed decisions about 
dose-adjustments. It should be noted that the nomogram can be used even if patients are 
on enzyme-inducing or inhibiting co-medications. The nomogram will always predict a 
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percentage of the previously administered dose and not an absolute value. Disease (e.g. 
liver) or physiological conditions (e.g. pregnancy) that lead to reduced binding will result 
in lower total concentrations. In this case the nomogram might under predict the needed 
increase in dose, which means that dose titration might take longer but there is reduced 
risk of achieving toxic concentrations. The Effect of drugs that displace VPA from 
plasma protein binding sites is more complex. In this case, factors to consider are the 
concentration of the displacer and its comparative affinity to VPA binding site. Since 
therapeutic VPA concentrations are in the order of 50-150 mg/l, presence of displacers 
(e.g. aspirin) might not affect the use of the nomogram in a clinically significant manner.  
 
            Population pharmacokinetics models were developed for unbound VPA 
concentrations and for plasma protein binding. The combined information was used to 
construct a model to simulate missed dose scenarios for 100 subjects. The simulation 
model accounted for the effect of missed doses in the study volunteers and can be used to 
make dosing recommendations when patients miss a scheduled administration. At the 
higher dose of 2000 mg, the release from the ER preparation was not extended for 22 h. 
Although dose dumping has not been reported to date with Depakote® ER, it is not 
recommended to take more than two tablets (1000 mg) at once. A make-up dose can be 
taken 12 h after the daily dose if a dose is missed from a 1000 mg ER regimen. If a 1000 
mg dose is taken 6 or 12 h late from schedule, then it should replaced as soon as possible. 
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Clinical Significance 
            Clinicians are divided on how to replace doses during therapy with VPA and it’s 
unethical to withhold therapy from patients with epilepsy to explore the effect of missed 
and delayed doses. This research provides dosing recommendations to the clinicians to 
counsel patients taking preparations of VPA in the event of a missed dose. The use and 
validation of VPA nomogram will foster the rational use of VPA for the treatment of 
epilepsy and its role in other neuropsychiatric disorders.  
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APPENDIX A 
 
CLINICAL STUDY PROTOCOL 
 
 
 
Title: A Prospective study to test a nomogram for valproic acid, a neuro psychiatric 
agent, and to   explore the effect of poor compliance on Depakote® extended release, a 
commercial preparation for valproic acid 
Study Site: Center for Drug Studies, School of Pharmacy, Virginia Commonwealth 
University, Richmond, VA 
 
Study Design: Open Label, Dose escalation and missed doses in healthy volunteers 
Principal Investigator: William R. Garnett, Pharm.D, Departments of Pharmacy and 
Neurology, VCU Medical Center, Richmond, VA. 
Medical Investigator: Larry Morton, MD. Department of Neurology. 
Co-investigators 
F. Douglas Boudinot, Ph.D. Department of Pharmaceutics. (Supervision and data 
analysis) 
William H. Barr PharmD., Ph.D., Department of Pharmacy, Center for drug studies. 
(Supervision) 
Alaa Ahmad, B.S. Pharm., Department of Pharmaceutics. (Analytical, in vitro study, data 
analysis, manuscript write-up) 
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ABBREVIATIONS 
 
 AE   adverse event 
 BP  blood pressure 
 CBC  complete blood count 
 CNS  central nervous system 
 C-T  Concentration Time 
 DR  Delayed Release 
 DSMC  Data Safety Monitoring Committee  
 ECG  electrocardiogram 
 ER  Extended Release 
 FDA  Federal Drug Administration 
 GCP  Good Clinical Practice 
 G1  Group 1 
 G2  Group 2 
 G3  Group 3 
 hCG  urine pregnancy test 
 HR  heart rate 
 IRB  Internal Review Board 
             n  number (e.g., number of volunteers) 
             U/A  urinary analysis (Lab Tests) 
 VCU  Virginia Commonwealth University 
 VPA  valporic acid 
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1.0 Background 
 
Since its first clinical use in France in 1967, valproic acid (VPA), rapidly became a major 
anti-epileptic drug worldwide. VPA is recognized as a highly effective first-line drug 
against the generalized seizures encountered in idiopathic or primary generalized 
epilepsy, including absence, generalized tonic-clonic and myoclonic seizures. It is also 
used in bipolar disorders and for the prophylaxis of migraine (1, 2). Valproic acid has an 
interesting pharmacokinetic /pharmacodynamic profile. It binds extensively to plasma 
proteins; at therapeutic concentrations, bound VPA comprises 90% of total VPA. This 
binding is also non-linear; binding site(s) saturate at higher doses affecting the clearance 
and volume of distribution of total VPA. The kinetics of unbound VPA, however, 
remains linear. This means that unbound or free VPA levels increases proportionally with 
dose while total VPA levels increases less than proportionally. It is widely accepted that 
the free form of the drug is the one that is associated with pharmacological actions and 
toxic effects. Although the analytical means to measure free VPA are available (1), total 
VPA levels are most commonly used in therapeutic drug monitoring during therapy with 
VPA. This has various implications. Of interest to our research is the effect of poor 
compliance, in terms of delayed and/or missed doses from schedule, on two 
commercially available preparations for VPA. These are the Depakote® extended release 
and delayed release formulations (ER and DR respectively). We have recently completed 
a systematic characterization of the effect of poor compliance on the ER & DR 
preparations (3). The manuscript for this work, which involved Monte Carlo simulations, 
is in preparation. We have concluded from our simulations that Unbound VPA levels 
should be used for therapeutic monitoring since total levels show higher inter-individual 
variability and can under-estimate the effect of poor compliance. We plan to test the 
model used for the simulations in terms of its predictive power for the effect of poor 
compliance on the ER preparation.  
Recognizing that total VPA levels are still in use for therapeutic drug monitoring 
(although unbound VPA levels are more informative as stated earlier), we have 
developed a nomogram (Appendix 1) that can be used to predict percent (%) increase or 
decrease in dose needed to escalate or decrease total VPA levels (4). This nomogram was 
developed using simulations based on a two-saturable binding site model for the plasma 
protein binding of VPA (5, 6). Before recommending the nonmogram for clinical use, it is 
necessary to test the nomogram in a clinical study. Since the VPA nomogram is based on 
deterministic simulations, we plan to characterize the plasma protein binding of VPA in 
order to account for inter-individual variability in protein binding. This mixed effect 
modeling will allow individualizing the therapeutic drug monitoring of VPA based on 
total levels.    
 
2.0 Study Objectives 
 
1. To test the VPA nomogram. This will allow individualizing the therapeutic 
monitoring of VPA based on total levels.     
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2. To determine if VPA levels after missed doses in the population under study can 
be predicted from the simulations. This means that the population model used for 
the stochastic simulations is adequate, valid and can be used to make predictions 
regarding the steady state levels in the case of missed doses.  
3. To characterize the plasma protein binding of VPA in vitro. Additional 
knowledge obtained will be used to modify the nomogram to account for inter-
individual variability.  
 
3.0 Study Design 
 
This is an open-label, dose escalation, and missed doses study that will be performed in 
healthy volunteers (n=9). One of the study objectives is to develop a model for the 
binding parameters involved in the nonlinear binding of Valproic acid to albumin. This 
will be achieved by obtaining blank blood samples from subjects within one week before 
drug administration starts. Drug Administration will last up to 28 days; subjects will be 
housed in the Clinical Study Unit for 3 overnight stays during the course of the study. 
The study drug is a commercially available preparation of Valproic acid; the Depakote® 
extended release preparation (Depakote ER). The basic design of the study will involve 
escalating the dose of the ER preparation at three dosing levels: 500 mg, 750 mg & 1000 
mg, all given once daily; to achieve steady state at each dosing level. The purpose of the 
dose escalation is to test the VPA nomogram (appendix 1). Two blood samples will be 
taken to confirm steady state at each dosing level. After dose escalation, subjects will be 
randomized into three groups (on day 21: G1, G2, and G3), each of which will miss a 
scheduled ER dose at a certain time. Thirteen (13) blood samples will be withdrawn from 
subjects in each group, following the missed dose, to characterize the concentration-time 
(C-T) profile of both free and total VPA. The C-T profile following missed doses is 
needed to test the outcome of a stochastic model for missed doses. After the completion 
of blood sampling for missed doses, Depakote dose will be tapered off as a precautionary 
measure. Subjects will be monitored for side effects during all phases of the study and 
vital signs recorded.   
 
3.1 Subject Selection 
 
Inclusion criteria  
 
1. Males or females, in the age range of 18-55 years (inclusive). 
2. Healthy volunteers with no clinically relevant abnormalities as determined by: 
medical history, Physical examination, blood chemistry, complete blood count 
(CBC), and urine analysis. 
3. Negative test for drugs of abuse (LIST) 
4. Subjects must be within normal limits of weight (± 30%). 
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5. Subjects not taking any other medications during the study that might produce drug-
drug interactions with the valproic acid.  
6. Due to teratogenic effects of VPA, women of childbearing potential will be included 
in the study provided that they are not nursing and practice an acceptable form of 
contraception. A urine hCG test will be performed to rule out pregnancy. 
7. Subjects must be non-smokers. 
 
Exclusion criteria   
 
1. Subjects with known hypersensitivity to the valproic acid. 
2. Subjects with liver function tests those are greater than two times the upper normal 
limit or active liver disease.  
3. Subjects with known urea cycle disorders   
4. Donation or receipt of whole blood or blood products within 3 months of study day 
1. 
5. Subjects with albumin concentration < 0.35 g/dl. 
6. Participation in a clinical study for an investigational drug, device, or procedure for 
a period of 2 months prior to the first day of the study. 
7. Subjects with any disease states that might affect the pharmacokinetics of VPA. 
8. History of vaso-vagal reaction or “feeling faint” during blood collections. 
9. A hematocrit level below 40% for males and females. 
10. Any personnel involved with the study at the investigational site 
11. Unable to refrain from alcohol the duration of the study and within 48 hours of entry 
during the inpatient phase. 
  
3.2 Screening 
 
Prior to the initiation of the study, subjects will be fully informed of the study plan, 
procedures and risks involved in participating in the study, and will be asked to sign and 
date the Informed Consent Form (ICF). Once a subject has agreed to participate and 
signed the informed consent, they will be screened (screening window is 28 days), in 
order to establish eligibility. The volunteers will receive a medical examination, 
consisting of a medical history, brief physical examination, 12-lead ECG, Vital Signs 
(BP, HR) and laboratory tests (Chemistries (SMA-18), CBC with Hematocrit, U/A, HIV, 
Urine Drug Screen, Urine Pregnancy test for females). Albumin concentration will be 
measured because it is an important determinant of the kinetics of VPA. The normal 
range for albumin concentration is 3.4-5.4 g/dl or 0.4857-0.7714 mM.  
 
3.3 Study Assessments and Procedures 
 
Eligible subjects (based on screening procedures described above and in appendix 3) are 
required to donate 100 ml of blood within one week before drug administration starts. 
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Blank blood will be centrifuged to obtain plasma and stored at -70 ◦ C. Blank plasma 
from study subjects will be used to characterize the plasma protein binding of VPA in 
vitro. Briefly, serial concentrations of VPA ranging from 0-200 mg/l will be prepared in 
plasma. Following mixing under 37 ◦ C for 1 hour, Unbound VPA will be determined 
using ultra filtration. Bound VPA will be calculated as: nominal concentration – unbound 
concentration. Data analysis is described below.   
 
Details of study procedure are described in appendix 3. Dose Escalation, Missed doses, 
and Dose Tapering Phases are described below. 
 
3.3 .1 Dose Escalation (See study schema: appendix 2) 
 
Subjects will be administered three different doses to reach steady state: 
 
1. 500 mg once daily (8:00 am) for seven days to achieve steady state (Study days 1-7). 
2. 750 mg once daily (8:00 am) for seven days to achieve steady state (Study days 8-14) 
3. 1000 mg once daily (8:00 am) for seven days to achieve steady state (Study days 15-
21) 
 
Note: All blood samples are 7 ml each. Both free and total VPA will be determined. 
The purpose of dose escalation is to test the nomogram. In order to confirm steady state, 
two blood samples will be taken from each subject. The two samples will measure the 
trough level (Minimum concentration, Cmin) and will be taken before the daily doses 
(8:00 am) on the following study days: 1, 7, 8, 14, 15, 21 and 22.  
 
3.3 .2 Missed doses 
 
On day 21 of the study, subjects will be randomized into 3 groups each consisting of 3 
subjects: 
1- Group 1 (G1): will take 1000 mg ER at 14:00 (six (6) hours late from schedule) 
2- Group 2 (G2): will take 1000 mg ER at 20:00 (twelve (12) hours late from schedule)  
3- Group 3 (G3): will not take any dose i.e. miss ER dose  
 
Serial blood sampling will be conducted for each group as detailed in appendix 2. 
Total number of samples withdrawn from each subject is 20.  
 
3.3.3 Dose tapering  
 
ER dose will be tapered off for each subject after completion of the Pharmacokinetic 
Sampling (Day 22-24) as shown in the study schema (appendix 2).  
 
3.3.4 Exit Procedure 
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At the completion of the inpatient phase of the study procedures, the volunteer will have 
the following exit procedures: brief physical exam, ECG, Vital Signs (BP, HR) and 
Adverse Event evaluation. Volunteers will be discharged when it’s clear that there are no 
complications. The Medical Investigator or his designee will authorize release of the 
volunteer.  Volunteers will return after dose tapering for a follow-up visit (Vital Signs 
(BP, HR) and Adverse Event evaluation). 
 
3.4 Meals 
 
There will be no food or water restriction. Standardized meals will be served to subjects 
while on site (Breakfast will be served 2 hours post dose, other meals during missed 
doses will be served at the designated times). 
 
 Breakfast Lunch Dinner 
Day 21   G1, G2, G3 
Day 22 G1, G2, G3 G1, G2, G3 G1, G2, G3 
Day 23 G1, G2, G3 G1, G2, G3 G1, G2, G3 
Day 24 G1, G2, G3   
 
3.5 Drug Storage, Dispensing and Methods of Administration 
 
Depakote ER preparation will be stored at room temperature and constant humidity 
conditions in the CDS pharmacy.  CDS pharmacy technicians and investigators will be 
responsible for the preparation and dispensing to study subjects each period and while 
subjects are in the CDS. Study drug will be administered orally with 100 ml water. 
Subjects are required to call in to the unit every morning to ensure compliance for 
outpatient dosing. 
  
3.6 Sample Collection, Handling and Storage 
 
Samples will be collected in suitable heparinized glass or plastic collection centrifuge 
tubes. Blood will be centrifuged in a refrigerated centrifuge (4 o C) at 3000 rpm (1500g) 
for 10 minutes. Plasma will be harvested into Teflon capped, silanized tubes labeled 
(Study #, Subject #, Collection Time, Date), and stored in an alarmed –70o C freezer. All 
collection, centrifuge and storage times will be immediately recorded on the appropriate 
source documents.  
 
3.7 Timed Event Schedule  
 
See Appendix 3. 
 
3.8 Analytical Methodology 
 
  
  
119
Total and unbound VPA plasma concentrations will be determined using a commercially 
available fluorescence polarization immunoassay (FPAI) on the TDx/TDx FLx system 
(Abbott Laboratories, Abbott Park, IL, USA). Ultra filtration will be used to separate 
unbound drug. Reports in the literature almost invariably report a coefficient of variation 
of less than 10 % for the assay. The lower limits of quantification for total and unbound 
VPA in plasma were 12.5 and 2 mg/L, respectively (5).    
 
3.9 Statistical Considerations  
 
3.9.1 Sample size 
 
No formal power calculations were performed. This study is a carried out as proof of 
concept for predictions provided by the stochastic and deterministic simulations. 
 
3.9.2 Randomization and Blinding  
 
On day 22 of the study, subjects will be randomized into 3 groups each consisting of 3 
subjects: 
1- Group 1 (G1): will take 1000 mg ER at 14:00 (six (6) hours late from schedule) 
2- Group 2 (G2): will take 1000 mg ER at 20:00 (twelve (12) hours late from schedule)  
3- Group 3 (G3): will not take any dose i.e. miss ER dose  
 
Blinding is irrelevant in this study. 
 
3.9.3 Demographics and patient characteristics  
 
Demographics and important patient variables will be summarized for all subjects. 
 
4.0 Data Analysis 
 
1- Blood samples taken during dose escalation (two at each dosing level) will be used to 
test the nomogram based on total levels.  
To illustrate how the nomogram works, here is an example: 
To elevate total VPA levels from 50 mg/l to 75 mg/l we predict that dose should be 
increased by 104% (4). The nomogram is shown below. 
 
2- Plasma protein binding of VPA will be characterized using blank plasma taken from 
the study subjects before the study conduct. Free and total VPA will be measured to 
calculate bound VPA. Protein binding models incorporating one saturable site, two 
saturable sites, and two sites: one saturable, one non-saturable will be challenged to 
achieve best fit. 
These models are: 
a- One saturable site: Cb= (NKCuP)/(1+KCu) 
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b- Two saturable sites: Cb= (N1K1CuP)/ (1+K1Cu) + (N2K2CuP)/ (1+K2Cu) 
c- Two sites: one saturable, one non-saturable:  
 
Cb= (N1K1CuP)/(1+K1Cu)+[(N2K2)CuP] 
 
Common to all equations, bound VPA will be calculated from: 
Cb = Ctot - Cu 
Where: 
Cb = bound VPA 
Cu = Unbound VPA 
Ctot = Total VPA 
P is albumin concentration (will be measured chemically) 
N1 & N2 represent the number of binding sites per class of binding site; K1 & K2 are the 
affinity (association) constants for the two binding sites. N, K are the corresponding 
parameters for one-binding site.  
3- Trough levels after the missed doses and Cmax’s after dose double-up will be used to 
test the predictions of the stochastic simulations. 
 
5.0 Duration of Study 
 
This study will last approximately 28 days. Subjects will be taking study drug during the 
out patient phase to reach steady state for each dose escalation, prior to each dose 
escalation subjects will enter the CDS unit for a trough level (PK blood sample). On the 
evening of day 21 subjects will enter the CDS unit and remain for the Pharmacokinetic 
portion of the study.  Each subject will spend approximately 36-48 hours at the VCU 
Center for Drug Studies including three overnight stays. See Timed Events Schedule, 
Appendix 3. 
 
6.0 Recruitment for All Groups 
 
Volunteers will first be recruited from the CDS database. If necessary, advertising will 
also be used to recruit volunteers. 
 
Subject Withdrawal or Dropout 
 
All volunteers are free to withdraw from the study at any time for any reason, and 
without prejudice to further treatment. Volunteers may also be withdrawn from the study 
by the Medical Investigator Dr. Larry Morton.  If a subject withdraws from the study 
prior to completion of all parts of the study, collection of data should be as complete as 
possible. The reason for withdrawal must be recorded in the CRF. 
 
Any subject who has been randomized but does not complete the study may be replaced 
and a new randomization number must be used for the replacement subject.   
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An attempt will be made to get 9 completed volunteers. However, no more than 12 
volunteers will be entered into the study. 
 
7.0 Adverse Events  
 
            Any adverse event, including both observed and volunteered problems, complaints, or 
symptoms are to be recorded on the Adverse Event page of the CRF. The need to capture 
this information is not dependent upon whether the adverse event is associated with the 
use of the treatment. In order to avoid vague, ambiguous, or colloquial expressions, the 
adverse event should be recorded in standard medical terminology.  Each adverse event is 
to be evaluated for onset, duration, frequency, intensity, severity, relationship to study 
product, action taken, and the outcome. 
 
Adverse Event Definitions 
 
            The investigator will be asked to identify any adverse events in accordance with Good 
Clinical Practice (GCP).  An adverse event is defined as any reaction, side effect, or 
untoward event that occurs during the course of the clinical trial, whether or not the event 
is considered study product related. 
 
A serious adverse event (SAE) is defined as any adverse drug experience occurring at any 
dose that results in any of the following outcome: 
 
• death, 
• a life-threatening adverse drug experience, 
• inpatient hospitalization, 
• results in a persistent or significant disability/incapacity, 
• a congenital anomaly/birth defect 
 
Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered a serious adverse drug experience when, based upon 
appropriate medical judgment, they may jeopardize the patient and may require medical 
or surgical intervention to prevent one of the outcomes listed in this definition.   
 
Any adverse experience, the specificity or severity of which is not consistent with risk 
information described in the general investigational plan, is considered an unexpected 
adverse event. 
 
a) Definitions of Intensity 
 
The intensity of an Adverse Event is a relative estimate made by the investigator. 
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Mild The adverse event is transient and easily tolerated by the patient and 
requires no special treatment 
 
Moderate The adverse event causes the patient discomfort that may be ameliorated 
by simple therapeutic measures 
 
Severe The adverse event is incapacitating, simple therapeutics do not ameliorate 
the event. 
 
b) Relationship to Study Treatment 
 
The investigator will determine the relation of each adverse event to the study product 
using one of the following categories: 
 
Definite The adverse event – including laboratory test abnormality - has a timely 
relationship to administration of the study product and there is no 
apparent, potential alternate etiology 
 
Possible The adverse event – including laboratory test abnormality - has a timely 
relationship to administration of the treatment and there is an apparent, 
potential alternate etiology 
 
Not Related   The adverse event is related to an etiology other than 
                       administration of study product 
 
Not Assessable        An adverse event for which sufficient information is not  
available to allow a reasonable assessment. The assessment should 
be performed later, if possible. 
 
c) Definitions of Action Taken 
 
The action taken as a result of the adverse event will be classified in one of 
 the following categories: 
 
None   No action taken 
 
Other therapy Drug or other therapy was initiated to counteract the adverse event 
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Emergency Contacts 
 
The investigator will report the SAE to the Institutional Review Board (IRB). 
 
Copies of the adverse event forms are located in the CRF booklet for each patient. 
 
 
8.0 Data Collection Management 
 
Any treatment-emergent signs and symptoms (TESS), defined as adverse events 
(AEs) that have first occurred or worsened in severity after initiation of the study 
procedures, will be reported and recorded on the CRFs.   
8.1 Source Documents / Retention of Data 
 
The principal investigator will prepare and maintain adequate and accurate records for 
each volunteer receiving either treatment or study procedure. Source documents such as 
hospital, clinic or office records, laboratory reports, study worksheets and the signed 
informed consent must be included in the investigator’s files with the volunteer’s records. 
 
9.0 Protection Of Human Subjects 
 
9.1 Ethical Regulations 
 
The study will be carried out in accordance with the International Code on 
Harmonization (ICH) Guidelines for Good Clinical Practice (January 17, 1997) and with 
the Declaration of Helsinki, revised version, 2000 Edinburgh, as well as per the U.S. 
Code of Federal Regulations. 
 
9.2 Subject Safety and Confidentiality 
 
Data Safety Monitoring Board 
The Investigators will be responsible for data and safety monitoring during the study. The 
review will include protocol compliance with inclusion/exclusion criteria, gender and 
minority, and adverse events. The protocol will undergo its initial review by the study 
team after at least 3 subjects have been enrolled, with follow-up review at the end of the 
study since this study is not high risk. 
Subject safety 
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All subjects will be monitored for side effects. Subjects who show signs of toxicity or 
intolerance will be withdrawn from the study. Volume of blood withdrawn from subjects 
is 233 ml (~1/2 pint).  
 
Inclusion of Women 
 
There will be no restriction regarding inclusion of women in the study. However, Women 
of childbearing potential will be included provided that they are not nursing and practice 
an adequate and acceptable form of birth control. General inclusion criteria involve the 
recruitment of healthy women ages 18-55.  
 
Inclusion of Minorities 
 
Minorities will be included in the study. The percentage will depend on recruitment. 
General inclusion criteria involve the recruitment of healthy subjects ages 18-55.  
 
Inclusion of Children 
 
Children will not be included in the study since the research topic is not relevant to 
children. 
 
9.3 Protection of Human Subjects 
 
Risks to subjects 
 
As mentioned above, blood samples will be taken from subjects to determine the 
concentration of VPA. Personal information including medical history will be taken at 
the patient interview to determine eligibility for the study and will not be disclosed to any 
other parties other than immediate study personnel. We do not expect the subjects to 
encounter undue health risks when taking the Depakote ER; subjects will be monitored 
for side effects and vitals signs during the study.  
 
Adequacy of protection against risks 
 
Information will be provided to prospective Subjects on the study goal and anticipated 
side effects. Each subject will sign a consent form after eligibility is established.  
 
Potential benefits of the proposed research to the subjects and others and importance of 
the knowledge to be gained 
 
Information obtained from the study will help avoid undue side effects for epileptic 
patients receiving the ER preparation. We expect that the outcome of the study will be to 
provide information that will help minimize the occurrence of break-through seizures and 
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CNS toxicity. The subjects are not expected to be at significant risk during the course of 
the study. 
 
Internal Review Board (IRB) 
 
As required, the protocol will be reviewed and approved by the VCU designated IRB 
(VCU IRB) before volunteers are enrolled in the study.  The Center for Drug Studies 
(CDS) complies strictly with the IRB approved protocol for study implementation, 
recruitment and advertising. In addition, the CDS follows GCP guidelines through their 
Standard Operating Polices. CDS is fully compliant with confidentiality issues now 
required by the HIPPA regulations. 
 
Subject Privacy 
 
The investigator confirms and upholds the principle of the patient’s right to protection 
against invasion of privacy. The data will be blinded correspondingly in all data analyses. 
No personal information will be disclosed to individuals other than direct study 
personnel. The principal investigator is responsible for keeping a Confidential Subject 
Identification list of all volunteers enrolled; including randomization numbers, and will 
maintain records of last known address and phone number. 
 
Individual patient medical information obtained as a result of this study is considered 
confidential and disclosure to third parties is prohibited. 
 
 
Informed Consent 
 
The investigator will ensure that each patient is given full and adequate verbal and 
written information about the nature, purpose, possible harm and benefit of the study. 
Volunteers must also be notified that they are free to discontinue their participation in the 
study at any time. The volunteer should have the opportunity to ask questions and be 
given time for consideration. The investigator or designee is responsible for obtaining 
signed informed consent from all volunteers prior to study initiation.   
 
The original signed informed consent will be retained with the study records, and a copy 
of the signed informed consent form will be given to the volunteers. 
 
10.0 Publication Of Results 
 
The data obtained from this study will be used as part of the Ph.D. dissertation for Alaa 
Ahmad. Manuscripts preparation will be a collaborative effort between the PI and all Co-
investigators.  
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11.0 Biohazard Containment 
 
Any materials used in this study that may present a biohazard, including but not limited 
to used syringes, needles, devices, blood samples, shall be handled using appropriate care 
to prevent transmission of potential infectious diseases. All such material will be 
discarded in compliance with all applicable institutional, local and other applicable rules 
and regulations. 
Special precautions will be made to prevent aerosolization of blood during the collection 
process. 
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13.0 Investigator Signature Agreement To Protocol 
 
I hereby declare that I have read the protocol and agree to the terms of this study 
protocol. I will conduct the study according to the procedures specified in the study 
protocol, and according to the principles of Good Clinical Practice. 
 
 
_____________________________________________________________ 
Printed Name of Investigator 
 
 
_____________________________________    _______________________ 
Signature of Investigator      Date 
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14. Informed Consent 
 
 
Investigators 
Principal Investigator: Dr. William R. Garnett, Pharm.D, Departments of Pharmacy of 
Neurology, VCU Medical Center, Richmond, VA.  
Dr. Larry Morton, MD. Department of Neurology. (Medical Investigator) 
Co-investigators 
Dr. F. Douglas Boudinot, Ph.D. Department of Pharmaceutics. 
Dr. William H. Barr, PharmD., Ph.D.,Department of Pharmacy, Center for Drug Studies. 
Alaa Ahmad, B.S. Pharm., Department of Pharmaceutics. 
1. Title of Research  
 
A Prospective study to test a nomogram for valproic acid, a neuro psychiatric agent, and 
to explore the effect of poor compliance on Depakote® extended release, a commercial 
preparation for valproic acid 
 
2. Introduction 
 
Valproic acid is a drug used to treat different neuro pschychiatric disorders including 
epilepsy, migraine and bipolar disorder. Depakote extended release (ER) is a new 
preparation for Valproic acid that can be taken once daily. The usual dose is 
approximately 1000 mg to 2500 mg per day, with some patients requiring higher doses. 
This study is being conducted to test a nomogram for Valproic acid. A nomogram is a 
chart that can aid in individualizing therapy with valproic acid to achieve better 
therapeutic outcome. This study will also explore the effect of poor compliance (i.e. 
missed doses) on valproic acid levels in the body. Since the study drug binds to albumin, 
a protein in your blood, we will characterize this binding using blood samples and use the 
data obtained to modify the nomogram to account for inter-individual differences.  
The screening phase precedes drug administration and might last up to 28 days. Within 
one week before drug administration starts, each eligible subject (based on screening) 
will be asked to donate 100 ml of blood. After screening is completed, drug 
administration will start and continue for 28 days according to the study schedule. Your 
total commitment to this study is therefore approximately two months, including the 
screening window. It is anticipated that at least nine, but no more than twelve volunteers, 
ages 18-55, will be enrolled in this study. 
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3.        Description of the study 
 
To qualify for this research study, you will have to provide written consent to participate 
in the research study and successfully pass an outpatient screening examination 
(Screening window is 28 days). Before you enter the study, your health will be assessed 
by a complete medical history including family history, physical examination, blood 
pressure and heart rate, laboratory screening (blood chemistries, complete blood cell 
count, urinalysis), and an electrocardiogram (ECG) (a measure of the electrical activity of 
the heart), to determine if you have any medical condition that would prevent you from 
participating in this research study. The outpatient screening examination will include a 
urine test for drugs of abuse, and an alcohol breath test, and will be repeated again on the 
day you are admitted to the study before your first treatment dose. Eligible subjects; 
based on screening, are required to donate 100 ml of blood within one week before drug 
administration starts. 
 
Throughout this study, multiple blood samples will be taken either by direct venipuncture 
(insertion of a small needle into a vein in the arm) or through a heparin lock (a small 
plastic catheter inserted into a vein in your arm used to take small blood samples) at 
frequent. The total blood volume collected throughout the study will be approximately 
250 ml (~ ½ pint). This is close to half the amount you would give at a single blood 
donation (450ml, less than one pint).  
 
Drug administration will start after at least nine (9) eligible subjects have been recruited, 
signed their informed consent form and donated 100 ml of blood.  
You are required to come to the clinic on day one (1) of the drug administration period to 
have a baseline blood sample taken and be given a dose of (500 mg) Depakote on the 
unit. You will also be given five (5) more doses (500 mg each) to take for the next five 
(5) days (study days 2-6), which you will take at home. You are required to call the unit 
on those days to document that you have taken your dose. On day seven (7), you will 
come for a blood sample prior to 8:00 am and take (500 mg) dose at the study unit. First 
dose increase, on day 8, you will come back to the clinic for another blood sample prior 
to 8:00 am and you will given (750 mg) dose plus five (5) more (750 mg) doses for the 
next five (5) days of the study (study days 8-13). You are required to call the unit each 
time you take your dose. On day 14, you will come to the clinic for a blood sample prior 
to 8:00 am and be given (750 mg) dose. Second dose increase, on day 15, you will come 
for another blood sample prior to 8:00 am and be given (1000 mg) dose on the unit, plus 
five (5) more (1000 mg) doses to take on days (16-20). You must call the unit each time 
you take your dose. On day 21, you will come for a blood sample prior to 8:00 am and 
take (1000 mg) dose on the unit.  
 
You will come back in the evening of day 21 to start the in-patient phase of the study and 
the study investigators will assign you to one of three groups.  
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On day 22, a blood sample will be taken at 8:00 am.  
Group 1 will take (1000 mg) at 14:00, Group 2 will take (1000 mg) at 20:00, and Group 3 
will not take any dose on day 22.  
Group1 and Group 2 will have blood samples (13 total) starting on day 22 for 24 hours 
from the time they take their missed dose (14:00 (day 22) to 14:00 (day 23) for Group 1 
and 20:00 (day 22) to 20:00 (day 23) for Group 2). On day 23, Group 1 and Group 2 will 
take (1000 mg) at 8:00 am 
On day 23, Group 3 will take (2000 mg) at 8:00 am and have blood samples (13 total) for 
24 hours (from 8:00 (day 23)-8:00 (day 24)). 
 
On day 24, all subjects will take (1000 mg) at 8:00 am on the unit. All subjects will have 
exit procedures done before they leave the unit. These procedures include a physical 
exam, vital signs, 12-lead ECG, hematology, chemistry, urine analysis and adverse events 
assessment. The medical investigator or his designee will authorize your release. 
 
You will be given two (750 mg) and two (500 mg) doses to take over the next 4 days. On 
days 25 and 26 of the study, you will take (750 mg) at 8:00 am. On days 27 & 28, you 
will take (500 mg) at 8:00 am. You are required to call the unit to document when you 
take your study medication as before. You should complete this study in approximately 
28 days. You will have to return to the unit within one week after your last dose for a 
follow-up visit; at this time you will have Vital Signs and Adverse Event evaluation. 
 
Over the course of the study you will have to spend approximately two days and three 
nights at the Center for Drug Studies, Clinical Study Unit. While you are on the Clinical 
Study Unit, you will eat the food provided by the investigators at times specified, and 
will abide by the rules of the Clinical Study Unit. Portions of the inpatient screening 
examination will be repeated at the end of the study and are requirements for completing 
the study.  
 
This study is being conducted at the Center for Drug Studies, Virginia Commonwealth 
University, VCU Medical Center, by Dr. William Garnett, Pharm.D, Departments of 
Pharmacy and Neurology, Dr. Douglas Boudinot, Ph.D, Department of Pharmaceutics, 
Dr. William Barr, Pharm.D, Ph.D, Department of Pharmacy, Alaa Ahmad, Ph.D 
candidate, Department of Pharmaceutics and Dr. Larry Morton, M.D., Department of 
Neurology.  
 
Dr. Larry Morton is the first investigator that you should contact in the event of a medical 
emergency.  
 
3. Benefits 
 
You are being asked to participate in this study as a volunteer. This study is of no direct 
medical benefit to you. There will be no charge to you for the screening examination and 
the results will be made available to you if you want them. 
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In order to achieve the total number of volunteers to complete the study per protocol, it is 
often necessary to recruit, screen additional volunteers (alternates). If you qualify as a 
volunteer and check in to the Clinical Studies Unit, but do not receive the study drug, you 
will receive a $100.00 payment.  You will be paid $ $1,240.00 for full completion of the 
study. Conditions for early withdrawal are described in Section 10. 
 
4. Alternative Therapy 
 
There is no therapeutic benefit to you in this study. Your participation is entirely 
voluntary.   
 
5. Risks, Inconveniences, Discomforts 
 
The most common side effects for valproic acid are nausea, dyspepsia, diarrhea, 
vomiting, abdominal pain, somnolence, edema, weight gain, tremors and hair loss. Other 
side effects may occur.  
There may be some local discomfort, pain or bruising at the site of the venipuncture. 
Rarely, fainting or infection may occur. In the event that an indwelling catheter (heparin 
lock) cannot be inserted, it may be necessary to obtain sample(s) by venipuncture 
(directly inserting needle into vein of arm to withdraw blood sample).   
 
LIST OTHER RISKS ASSOCIATED WITH THE STUDY. 
 
You will be informed of any changes in the study and of any new risks, which become 
evident. You will be questioned for any symptoms, which you may experience during the 
study. You should report immediately any subjective feelings, symptoms, or changes, 
which you experience during the study. 
 
6. Cost of Participation 
 
There will be no charge to you for any laboratory tests, physical examination, study drug, 
any over-the-counter products provided, or housing that relates to the conduct of this 
study.   
 
This is not a time consuming study and should not interfere with your employment, 
school, or other activities. Participation should not interfere with your normal activities 
after this study, but this cannot be guaranteed because some side effects may occur. 
 
7. Research Related Injury 
 
In the event of physical and/or mental injury resulting from your participation in this 
research project, Virginia Commonwealth University and VCU Medical Center Hospitals 
will not provide compensation. If injury occurs, medical treatment will be available at the 
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VCU Medical Center Hospitals. If you are injured during this research study, and the 
injury is a direct result of the effects of the study drug or procedures, the cost of 
reasonable emergency medical treatment will be paid by the Study investigator provided 
that you have not violated the stipulations of the protocol (for example, alcohol 
consumption, other drugs, or failure to follow the instructions of the investigators). 
However, such reimbursement by the sponsor shall be limited to medical expenses not 
otherwise covered by existing health care programs or insurance policies. No other 
compensation will be provided by the study investigator. It is necessary that you notify 
the investigators in person or in writing of the nature of expenses to be covered. Financial 
compensation for items such as lost wages; disability or discomfort is not available.   
 
8. Pregnancy 
 
Every effort will be made to have females enter this study on an equal basis with male 
volunteers.  Females who are on adequate form of birth control will be entered into this 
study. Female volunteers participating in this study should not be nursing or pregnant. If 
pregnancy were to occur, there is a risk of birth defects. A pregnancy test will be 
performed on female volunteers prior to administration of the study medication. A 
positive pregnancy test will exclude you from participation in the study.   
 
9. Confidentiality of Records 
 
In connection with this study, it is important for the investigators, as well as your 
personal physician and the Institutional Review Board (IRB) to be able to inspect your 
medical records.  Therefore, you authorize the investigators to release your medical 
records to the study investigators, the FDA, and the IRB.  The results of this study may 
also be used for medical and scientific publications, but your identity will not be 
disclosed. 
 
10. Withdrawal 
 
Your participation in this study is entirely voluntary. The investigators will answer any 
questions you may have about the study. You are free to withdraw your consent and 
discontinue participation at any time. If you decide to withdraw from this study, you 
should contact the Principal Investigator, Dr. William Garnett. Discontinuation will in no 
way affect the care you receive now or in the future at this institution. Your doctor may 
also withdraw you for medical reasons. If during the course of the study your medical 
condition changes or you experience adverse side effects, your participation may be 
terminated by the investigator without your consent. Any significant new findings which 
develop during the course of the research study that may affect your willingness to 
participate will be provided to you. If you are withdrawn from the study for medical 
reasons, based upon the judgment of the medical investigator, or elect to withdraw, you 
will receive a prorated compensation based upon the usable information obtained prior to 
your withdrawal. If you are removed from the study for any of the following reasons, you 
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will receive no compensation: (1) Failure to give an accurate history; (2) Failure to follow 
the guidelines of the study; (3) Failure to follow the rules of the unit. If you should 
discontinue participation in this study, you understand that a physical examination, vital 
signs, an ECG and an evaluation of your laboratory data (complete blood count, blood 
chemistries and urinalysis) will be repeated for your safety as part of the required study 
termination procedures. 
 
11. Current Telephone Numbers 
 
You have been given the opportunity to ask questions that you may have.  If you have 
questions or if you experience any side effects, you can contact the investigators at: 
                                       
                                                         
 Work Home Pager/Cell 
Dr. William 
Garnett 
828-8328 804-378-4222 804-997-9050 
Alaa Ahmad 828-6215 804-262-7889 804-502-0467 
Dr. Larry Morton 828-0422  828-4999 ext. 3594 
Clinical Study Unit
  
828-5522   
 
In the case of a medical emergency, you should contact Dr. Larry Morton at the above 
number. 
 
12. Subjects Rights Information 
 
If you want additional information about your rights as a research subject, you may 
contact the Chairman of the Committee on the Conduct of Human Research at Virginia 
Commonwealth University/VCU Medical Center at (804) 828-0868. 
 
You will be given a copy of this consent form to keep. 
 
Your signature below indicates that you voluntarily consent to participate in this study 
under the conditions disclosed in this document. 
 
______________________________   ____________________ 
Subjects Signature      Date 
_______________________________   ____________________ 
Subjects Printed Name     Date 
 
_______________________________   ____________________ 
Witness       Date 
________________________________   ____________________ 
Investigators Signature     Date 
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Appendix 2 (Study Schema) 
 
Day ER Dose    
(mg) Time of dose Blood sampling (nominal time) 
1 500 8:00 am Baseline level 
2 500 8:00 am ------ 
3 500 8:00 am ------ 
4 500 8:00 am ------ 
5 500 8:00 am ------ 
6 500 8:00 am ------ 
7 500 8:00 am Trough at 8:00 am 
8 750 8:00 am Trough at 8:00 am 
9 750 8:00 am ------ 
10 750 8:00 am ------ 
11 750 8:00 am ------ 
12 750 8:00 am ------ 
13 750 8:00 am ------ 
14 750 8:00 am Trough at 8:00 am 
15 1000 8:00 am Trough at 8:00 am 
16 1000 8:00 am ------ 
17 1000 8:00 am ------ 
18 1000 8:00 am ------ 
19 1000 8:00 am ------ 
20 1000 8:00 am ------ 
21 1000 8:00 am Trough at 8:00 am 
22       G1   
G2   
       G3   
    1000 
    1000 
   Missed 
14:00 pm 
20:00 pm 
----------- 
Trough at 8:00 am, 14:00, 16:00, 18:00, 20:00, 22:00, 00:00. 
Trough at 8:00 am, 20:00, 22:00, 00:00. 
Trough at 8:00 am 
23   G1   
G2   
G3         
1000 
1000 
 
2000 
8:00 am 
8:00 am 
 
8:00 am 
02:00, 04:00, 06:00, 08:00, 10:00, 12:00, 14:00. 
02:00, 04:00, 06:00, 08:00, 10:00, 12:00, 14:00, 16:00, 18:00, 20:00 
 
08:00, 10:00, 12:00, 14:00, 16:00, 18:00, 20:00, 22:00, 00:00. 
24   G1   
G2   
       G3   
1000 
1000 
1000 
8:00 am 
8:00 am 
8:00 am 
------ 
------ 
02:00,04:00, 06:00, 08:00. 
25   G1   
G2   
       G3   
750 
750 
750 
8:00 am 
8:00 am 
8:00 am 
------ 
------ 
------ 
26   G1   
G2   
       G3   
750 
750 
750 
8:00 am 
8:00 am 
8:00 am 
------ 
------ 
------ 
27   G1   
G2   
       G3   
500 
500 
500 
8:00 am 
8:00 am 
8:00 am 
------ 
------ 
------ 
28   G1   
G2   
       G3   
500 
500 
500 
8:00 am 
8:00 am 
8:00 am 
------ 
------ 
------ 
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Appendix 3 
 
Schedule of Events 
Pre-Study 
Screening 
 
Study 
Days 
 
Exit /Early 
Withdrawal 
Study Procedures 
 
 
-28 to – 1 
 
1-28 
 
Informed Consent X   
Demographics X   
Medical History X   
Medication History X   
Physical Exam a X  X 
Vital Signs b X X X 
12-Lead ECG c  X  X 
Hematology d  X X X 
Chemistry d X X X 
(HCG) Serum Pregnancy (if applicable) d X   
Urine Drug Screen d  X   
HIV test d X   
Urinalysis d X X X 
Alcohol breathalyzer e X   
PK sampling (plasma) f   X  
Drug Administration g     X  
Adverse Event Assessment h   X X 
Concomitant Medication Assessment h  X X 
a) Physical Exam will be done at screening and exit from study unit. 
b) Vital Signs (BP/HR) will be done at screening and  prior to dosing on days 7, 8, 14,15, 21 22, 23,24 and at 
exit 
c) 12-Lead ECG will be done at screening and exit from study unit. 
d) Labs (CBC, Chem, hCG, UDS, U/A, HIV will be done at screening, Labs (CBC, Chem, U/A) 
will be done at exit from study unit. 
e) Alcohol breath test will be done at screening (for 100ml-blood work and day 1) and upon entry 
day 21 
f) PK blood sampling will be done prior to dosing (trough level) on days 1, 7, 8, 14, 15,21,22 all subjects  
Group 1: (3 subjects) will have additional samples at 0hr, 6hr, 8hr, 10hr, 12hr, 14hr, 16hr, 18hr, 
20hr, 22hr, 24hr, 26hr, 28hr, 30hr  on day 22-23  
Group 2: (3 subjects) will have additional samples at 0hr, 12hr, 14hr, 16hr,  18hr, 20hr, 22hr, 24hr, 
26hr,28hr,30hr, 32hr, 34hr, 36hr on days 22-23   
Group 3: (3 subjects) will have additional samples at 0hr, 2hr, 4hr, 6hr, 8hr, 10hr, 12hr, 14hr, 16hr, 
18hr, 20hr, 22hr, 24hr, on days 23-24  
g) Outpatient dosing: 
Days 2- 6(500mg), days 9- 13(750mg), days 16- 20(1000mg), days 24(1000mg), day 25-
26(750mg), day 27-28(500mg).  
    Inpatient dosing: 
Days 1, 7(500mg), days 8, 14 (750) 15 (1000 mg), days 21, 22, 23, 24 (1000 to 2000mg). 
h) Adverse Events and Concomitant Medication will be monitored continuously from screening throughout  
the study. 
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Abstract 
            (-)-D-β-Dioxolane-thymine (DOT) is a nucleoside analog with potent in vitro 
anti-HIV activity. A simple, rapid, accurate and reproducible reversed-phase HPLC 
method was developed to determine DOT in rat plasma. The extraction recovery of DOT 
was greater than 96%. DOT & D4T (internal standard) eluted at 6.9 and 9.8 minutes 
respectively. The limit of quantitation of the assay was 0.25 µg/ml. Intra-day and inter-
day precision and accuracy were acceptable. The assay was applied for investigation of 
preliminary disposition of DOT in rats after intravenous and oral administration.  
Keywords: (-)-D-β-Dioxolane-thymine, high performance liquid chromatography 
(HPLC),  
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1. Introduction 
  Acquired immune deficiency syndrome (AIDS) is caused by infection with the 
human immunodeficiency virus (HIV) [1]. An estimated 850,000-950,000 persons in the 
United States are living with human immunodeficiency virus (HIV), including 180,000-
280,000 who do not know they are infected [2]. In 2003, the estimated number of 
diagnoses of AIDS in the United States was 43,171. Adult and adolescent AIDS cases 
totaled 43,112 with 31,614 cases in males and 11,498 cases in females. Also in 2003, 
there were 59 AIDS cases estimated in children under age 13 [3]. Sixteen anti-viral 
agents have been approved for the treatment of HIV infection including the 
nucleoside/nucleotide reverse transcriptase (RT) inhibitors (ABC) abacavir, ddC 
(zalcitabine), ddI (didanosine), d4T (stavudine), 3TC (lamivudine), ZDV (zidovudine) 
and tenofovir, the non-nucleoside RT inhibitors delavirdine, nevirapine and efavirenz and 
the protease inhibitors ritonavir, saquinavir, indinavir, amprenavir, nelfinavir and 
lopinavir [4]. The natural history of HIV infection has been dramatically modified by the 
use of multi-drug highly active antiretroviral therapy (HAART) regimens. The 
recommended HAART regimens are all built around a backbone of two nucleoside 
analogs with either a protease inhibitor or non-nucleoside reverse transcriptase inhibitor. 
However, AIDS is still incurable, and current HAART regimens are unable to eradicate 
HIV infection. Thus, there are continuous efforts to develop more effective anti-HIV 
agents [5].  
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(-)-D-β-Dioxolane-thymine, DOT, (Figure B.1) is a nucleoside analog with potent 
in vitro anti-HIV activity. Racemic dioxolane-thymine, (±)-DT has been shown to 
provide a 50% protective effect against the infectivity and cytopathic effect of HIV-1 at 
20 µM. In contrast, AZT exerts a 50% protective effect at approximately 0.5 µM and a 
100% protective effect at 5 µM. AZT anti-retroviral activity, however, is accompanied by 
substantia+l in vitro toxicity: 11% at 5 µM and 50% at 50 µM [6]. The relative lack of 
toxicity exhibited by (±)-DT warranted further exploration of this compound and its 
enantiomers. The asymmetric synthesis of enantiomerically pure (-)-(1`R, 4`R)-
dioxolane-thymine and its anti-retroviral activity was reported by Chung K. Chu et al [7]. 
The anti-HIV activities of (±)-DT and its enantiomers in peripheral blood mononuclear 
cells (PBM) expressed as EC50 were 4.81 µM for (+)-L-β-dioxolane-thymine, 0.39 µM 
for (-)-D-β-dioxolane-thymine and 0.009 µM for (±)-DT, while that for AZT is 0.002 µM 
[8].  
Characterization of the preclinical pharmacokinetics of these potential antiviral 
agents is an integral part of drug development. Thus, development of an analytical 
methodology is essential for conducting preclinical investigations [9]. High-performance 
liquid chromatography has been shown to be an efficient, simple and relatively 
inexpensive technique for quantitating nucleoside analogs in biological samples [10-14]. 
The purpose of this study was to develop an HPLC assay for determination of (-)-D-β-
dioxolane-thymine (DOT) in rat plasma. This assay can be used for the quantitation of 
DOT after administration to rats to characterize the disposition in this animal model.  
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2. Experimental 
2.1. Chemicals 
(-)-D-β-Dioxolane-thymine was synthesized as previously described [7]. The 
chemical purity of DOT, as assessed by high performance liquid chromatography 
(HPLC) and spectral analysis, was greater than 99%. Internal standard, d4T, was 
purchased from Sigma-Aldrich Co. (St. Louis, Mo), acetonitrile (UV grade) was obtained 
from Burdick & Jackson (Muskegon, MI), sodium acetate trihydrate (HPLC grade) was 
obtained from Fisher Scientific (Fair Lawn, NJ), acetic acid (reagent grade) and octanol 
(reagent grade) were obtained from J.T Baker (Phillipsburg, NJ). All other reagents, 
analytical grade, were also obtained from J.T Baker (Phillipsburg, NJ). 
2.2. λmax, pKa and partition coefficient 
The wavelength of maximum absorption, λmax of DOT was determined by 
spectrophotometric scanning initially using a Perkin Elmer UV/VIS Spectrometer 
(Norwalk, CT) and confirmed with Shimadzu SPD-10A diode array detector (Columbia, 
MD).  The pKa of DOT was estimated by preparing 8 µM solutions of DOT in buffers of 
varying pHs and measuring absorbance at λmax.  Absorbance was plotted against pH to 
determine the acidity constant at the inflection point of the curve.  Mutually saturated 
water and octanol solutions were used for the partition coefficient determination at 37 °C.  
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DOT (100 µl of 1 µg/µl stock) was dissolved in 4ml water. This was mixed with 4.1 ml 
octanol and shaken for 24 h in a horizontal shaker (Lab-line Instruments Inc., Melrose, 
IL). After equilibration, the water phase was separated and the partition coefficient (PC) 
calculated from PC = (Co-Ce / Ce) where Co is the initial concentration in the aqueous 
phase and Ce is the concentration in water at equilibrium. 
2.3. Preparation of Standards 
Stock solutions of 1000 µg/ml, 250, 100, 25, 10 and 0.5 µg/ml DOT were 
prepared in distilled water. Stock solutions were added to rat plasma to obtain calibration 
concentrations of 0.25, 1, 3, 5, 10, 25 and 50 µg/ml DOT.  
2.4. Extraction Procedure 
                                    Extraction was achieved using a two-step centrifugation procedure. To 100 µl rat 
plasma in a polypropylene micro centrifuge tube were added 50 µl of d4T (50 µg/ml) as 
internal standard and 100 µl perchloric acid (2 M) to precipitate Plasma proteins. Tubes 
were vigorously mixed for 30 seconds and centrifuged at 13,000 rpm for 3 minutes. The 
supernatant was then transferred to a clean centrifuge tube and 100 µl (2 M) potassium 
hydroxide was added, samples mixed for 30 seconds and then centrifuged for 3 minutes 
at 13,000 rpm. Two hundred microliters (200 µl) of the supernatant was transferred to a 2 
ml vial and injected onto the HPLC column. Volumes of injection were variable 
depending on the concentration. 
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2.5. Chromatography 
A Shimadzu (Columbia, MD) HPLC system consisting of a SCL-10A System 
Controller, LC-10AT liquid chromatograph, DGU-14A degasser, SPD-10A diode array 
detector and SIL-10AD auto injector was used. The system was equipped with Shimadzu 
EZ start software package V7.2. The separation employed reversed-phase liquid 
chromatography using a Hypersil™ 5 µm BDS C18 analytical Column (4.6 x 250mm, 
Phase Separations, Franklin, MA) protected by a C18 guard column. The mobile phase 
consisted of 5% acetonitrile in 40 mM sodium acetate trihydrate with 100 µl of 5% acetic 
acid added to each liter of the mobile phase to optimize band spacing. The eluants were 
detected at 266 nm. The chromatography was performed at room temperature (23 ° C).  
2.6. Quantitation 
Concentrations of DOT were determined from the slope of calibration plots of the 
peak-area ratio of DOT/internal standard versus the calibration standard concentrations. 
Slopes were determined using linear regression analysis with a weighting factor of 
1/concentration. Shimadzu EZ start software package (v7.2) was used for regression.   
2.7. Assay Specifications 
The extraction recovery of DOT was assessed at plasma concentrations of 0.25, 
5.0 and 50 µg/ml. The recovery of internal standard was assessed at 50 µg/ml, at which it 
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was used for the assay.  Five plasma samples containing drug and internal standard were 
extracted and injected.  Five injections of the same amount of compound in distilled 
water were directly injected. The percentage recovery was calculated from (100 x peak 
areaextracted/peak areaunextracted).  
The intra- and inter-day precision and accuracy of the analytical method were 
determined by analysis of five plasma samples containing 0.25, 5.0, 50 µg/ml 
concentrations. Assay precision was determined by calculating relative standard 
deviations (%RSD) for each drug concentration. Accuracy was calculated by comparing 
measured concentrations to the known values and expressed as % mean accuracy. 
2.7. Experimental Design 
  Adult male Sprague Dawley rats (Hilltop Lab. Animals, Inc. Scottdale, PA) were 
used for the study. Animals were housed in a 12-h light/12-h dark, constant temperature 
(22°C) environment with free access to standard laboratory chow and water in the 
Virginia Commonwealth University Animal Care Facility, which is fully accredited by 
the American Association for the Accreditation of Laboratory Animal Care (AAALAC).                                 
Rats were acclimatized to this environment for at least one week before the study. 
Animal studies were approved by the Virginia Commonwealth University Animal Care 
and Use Committee and conducted in accordance with guidelines established by the 
Animal Welfare Act and the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals. 
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            External jugular vein cannulas were implanted under (ketamine : acepromazine : 
xylazine; 50:3.3:3.3 mg/kg) anesthesia the day before the experiment. Animals were 
fasted overnight, however, water was allowed ad libitum. DOT was administered 
intravenously to one rat by bolus injection via the jugular vein cannula and orally to one 
rat by gastric gavage. The animals were housed in metabolism cages following drug 
administration. Blood samples (0.25 ml) were collected from the cannulas into 
heparinized tubes prior to and at 0.083, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8 drug administration. 
Blood volume was replaced with normal saline (0.5-0.75 ml). Blood samples were 
immediately centrifuged and plasma was frozen at -20°C until analysis.  
3. Results and Discussion 
The purpose of this study was to develop an analytical HPLC method for 
determination of DOT in rat plasma. The physicochemical characteristics of DOT were 
evaluated.  Spectrophotometric scanning indicated that DOT has a λmax of 266 nm, an 
acidity constant of 9.4 and an oil/water partition coefficient of 0.2.  An isocratic HPLC 
method achieved adequate separation of DOT from the internal standard and any plasma 
peaks.  
Chromatograms of (a) blank rat plasma, (b) rat plasma containing DOT internal 
standard d4T, (c) a rat plasma sample collected 1 h after intravenous administration of 
DOT and (d) a rat plasma sample collected 1 h after oral administration of DOT are 
shown in Figure B.2. DOT and d4T eluted at 6.9 and 9.8 min, respectively. The assay 
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specifications including extraction recovery, assay precision and accuracy are presented 
in Table B.1. The extraction recovery of DOT averaged 98% (96-100%). The limit of 
quantitation of the assay was 0.25 µg/ml. A weighting factor of 1/concentration yielded a 
linear calibration curve from 0.25-50 µg/ml [y=0.042 (0.000329) x + 0.001645 
(0.001337), r=0.9999), n=7]. Intra-day and inter-day relative standard deviations of the 
assay were less than 15%. The accuracy of the method was greater than 95%. 
Plasma concentrations of DOT following intravenous and oral administration to 
rats determined by the assay described are illustrated in Figure B.3. 
In summary, the determination of DOT in rat plasma by the HPLC developed in 
the present study is simple, rapid, accurate and reproducible. The limit of quantitation of 
this method is sufficiently sensitive to characterize the preclinical pharmacokinetics of 
DOT in rats.  
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Table B.1 Assay specifications for DOT.  
 
 
 
 
 
 
 
 
    
Precision 
 
Accuracy 
 
Concentration 
(µg/ml) 
Recovery (%) 
 (Mean ± SD) 
Intra-day Inter-day Intra-day Inter-day 
0.25 100.0 ± 2.6  3.5 14.2 97.2 106.8 
5 96.0 ± 1.8 5.7 8.2 100.5 99.9 
50 98.3 ± 7.4  9.2 9.4 111.1 98.2 
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Figure B.1 Chemical Structure of (-)-D-β-dioxolane-thymine. 
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Figure B.2 Chromatograms of (a) blank rat plasma, (b) rat plasma with (1) 5 µg/ml of 
DOT and (2) 50 µg/ml internal standard added, (c) a rat plasma sample collected 1 h after 
intravenous administration of DOT to one rat and (d) a rat plasma sample collected 1 h 
after oral administration of DOT to a second rat. 
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Figure B.3 Concentration time-profiles following intravenous (circles) and oral 
administration (squares) of DOT to rats. 
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APPENDIX C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
  
154  
 
 
 
WINNONLIN OUTPUT 
 
 
WEIGHT 1/Yhat 
001 
WinNonlin Compartmental Modeling Analysis 
Version 4.0.1 Build 200210171634 
 
 
User-defined ASCII model: 
 
MODEL 
remark   ****************************************************** 
remark   Developer:  
remark   Model Date: 02-02-2005 
remark   Model Version: 1.0 
remark   ****************************************************** 
remark 
remark - define model-specific commands  
COMMANDS  
NFUNCTIONS 1 
NPARAMETERS 2 
PNAMES  'N', 'K' 
END 
remark - define temporary variables 
TEMPORARY  
CU=X 
END  
remark - define algebraic functions 
FUNCTION 1 
F= N*K*CU*0.714/(1+K*CU) 
END 
remark - define any secondary parameters 
remark - end of model 
EOM 
 
Settings for analysis: 
Input Workbook: C:\Program Files\Pharsight\WinNonlin\VPAPPB\001.pwo 
Input Worksheet: Sheet1 
Input Sort Keys: [none] 
Gauss-Newton (Levenberg and Hartley) method used 
Iterative reweighting used during minimization process 
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Convergence criteria of 0.0001 used during minimization process 
50 maximum iterations allowed during minimization process 
Input data: 
 
CU (mmol/l) CBbe CBaf Dbi-calc 
0.011388889 0.125277778 0.156041667 0.129514583 
0.015138889 0.157708333 0.205902778 0.170899306 
0.035277778 0.303958333 0.354375 0.29413125 
0.035833333 0.318819444 0.355972222 0.295456944 
0.057847222 0.367916667 0.465555556 0.386411111 
0.070694444 0.412361111 0.447013889 0.371021528 
0.108402778 0.519722222 0.562777778 0.467105556 
0.137916667 0.549444444 0.663333333 0.550566667 
0.193055556 0.717222222 0.720416667 0.597945833 
0.301736111 0.587986111 0.750208333 0.622672917 
0.423958333 0.685347222 0.759791667 0.630627083 
0.429513889 0.707569444 0.719791667 0.597427083 
0.447916667 0.741527778 0.734166667 0.609358333 
0.682638889 2.004861111 2.186805556 1.815048611 
0.695833333 1.854166667 2.600694444 2.158576389 
0.850694444 0.9 0.965138889 0.801065278 
1.470833333 1.272916667 1.658333333 1.376416667 
3.326388889 1.606944444 1.7375 1.442125 
4.211805556 1.172916667 2.232638889 1.853090278 
4.395833333 1.4 2.134722222 1.771819444 
9.694444444 0.419444444 2.980555556 2.473861111 
9.743055556 1.466666667 1.658333333 1.376416667 
11.20138889 0.747222222 1.673611111 1.389097222 
 
 
Output data: 
 
Initial Parameters 
 
Parameter Value Lower Upper
N 1 0 10 
K 11 0 110 
 
 
Minimization Process 
 
Iteration Weighted_SS N K 
0 17.0566 1 11 
1 3.78824 1.918 10.46 
2 2.82727 2.19 4.663 
3 2.62827 2.457 3.429 
3 2.62826 2.459 3.424 
 
 
Final Parameters 
 
N N_St
dErr
N_C
V% 
N_U
niva
N_U
niva
N_Pl
anar
N_Pl
anar
K K_S
tdEr
K_C
V%
K_U
niva
K_U
niva
K_P
lana
K_P
lana
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or rCI_
Low
er 
rCI_
Upp
er 
CI_
Low
er 
CI_
Upp
er 
ror rCI_
Low
er 
rCI_
Upp
er 
rCI_
Low
er 
rCI_
Upp
er 
2.45
8627 
0.26
8531 
10.9
2 
1.90
0191 
3.01
7063 
1.73
4195 
3.18
3060 
3.42
4069 
1.06
6849 
31.1
6 
1.20
5452 
5.64
2685 
0.54
5964 
6.30
2174 
 
 
Correlation Matrix 
 
Parameter N K 
N 1  
K -0.725898 1 
 
 
Eigenvalues 
 
Number Value 
1 3.795 
2 0.1063 
 
 
Condition Numbers 
 
Iteration Rank Condition 
0 2 4.994653 
1 2 4.046633 
2 2 3.139938 
3 2 2.910889 
 
 
Variance-Covariance Matrix 
 
Parameter N K 
N 7.21E-02  
K -0.207957 1.13817 
 
 
Summary Table 
 
CBbe CBaf CU_o
bs 
(mmol
/l) 
Dbi-
calc_o
bs 
CU 
(mmol
/l) 
Dbi-
calc 
Predic
ted 
Resid
ual 
Weigh
t 
SE_Y
hat 
Stand
ard_R
es 
0.1252
77778 
0.1560
41667 
0.0113
88889 
0.1295
14583 
0.0114 0.1295 0.0659 0.0636 15.162
9 
0.0154 0.7106
0.1577
08333 
0.2059
02778 
0.0151
38889 
0.1708
99306 
0.0151 0.1709 0.0865 0.0844 11.548
0 
0.0199 0.8258
0.3039
58333 
0.3543
75 
0.0352
77778 
0.2941
3125 
0.0353 0.2941 0.1892 0.1049 5.2808 0.0402 0.7061
0.3188
19444 
0.3559
72222 
0.0358
33333 
0.2954
56944 
0.0358 0.2955 0.1918 0.1036 5.2078 0.0407 0.6926
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0.3679
16667 
0.4655
55556 
0.0578
47222 
0.3864
11111 
0.0578 0.3864 0.2902 0.0962 3.4427 0.0568 0.5285
0.4123
61111 
0.4470
13889 
0.0706
94444 
0.3710
21528 
0.0707 0.3710 0.3421 0.0289 2.9206 0.0641 0.1468
0.5197
22222 
0.5627
77778 
0.1084
02778 
0.4671
05556 
0.1084 0.4671 0.4752 -
0.0081
2.1028 0.0788 -
0.0351
0.5494
44444 
0.6633
33333 
0.1379
16667 
0.5505
66667 
0.1379 0.5506 0.5631 -
0.0125
1.7747 0.0857 -
0.0498
0.7172
22222 
0.7204
16667 
0.1930
55556 
0.5979
45833 
0.1931 0.5979 0.6986 -
0.1007
1.4305 0.0920 -
0.3581
0.5879
86111 
0.7502
08333 
0.3017
36111 
0.6226
72917 
0.3017 0.6227 0.8920 -
0.2694
1.1205 0.0940 -
0.8399
0.6853
47222 
0.7597
91667 
0.4239
58333 
0.6306
27083 
0.4240 0.6306 1.0394 -
0.4088
0.9617 0.0925 -
1.1724
0.7075
69444 
0.7197
91667 
0.4295
13889 
0.5974
27083 
0.4295 0.5974 1.0449 -
0.4475
0.9566 0.0925 -
1.2797
0.7415
27778 
0.7341
66667 
0.4479
16667 
0.6093
58333 
0.4479 0.6094 1.0626 -
0.4533
0.9407 0.0923 -
1.2844
2.0048
61111 
2.1868
05556 
0.6826
38889 
1.8150
48611 
0.6826 1.8150 1.2295 0.5856 0.8131 0.0939 1.5373
1.8541
66667 
2.6006
94444 
0.6958
33333 
2.1585
76389 
0.6958 2.1586 1.2365 0.9221 0.8085 0.0942 2.4138
0.9 0.9651
38889 
0.8506
94444 
0.8010
65278 
0.8507 0.8011 1.3068 -
0.5058
0.7650 0.0981 -
1.2889
1.2729
16667 
1.6583
33333 
1.4708
33333 
1.3764
16667 
1.4708 1.3764 1.4646 -
0.0882
0.6826 0.1172 -
0.2142
1.6069
44444 
1.7375 3.3263
88889 
1.4421
25 
3.3264 1.4421 1.6138 -
0.1716
0.6196 0.1494 -
0.4049
1.1729
16667 
2.2326
38889 
4.2118
05556 
1.8530
90278 
4.2118 1.8531 1.6416 0.2115 0.6091 0.1568 0.4972
1.4 2.1347
22222 
4.3958
33333 
1.7718
19444 
4.3958 1.7718 1.6461 0.1257 0.6075 0.1581 0.2955
0.4194
44444 
2.9805
55556 
9.6944
44444 
2.4738
61111 
9.6944 2.4739 1.7041 0.7697 0.5868 0.1751 1.8012
1.4666
66667 
1.6583
33333 
9.7430
55556 
1.3764
16667 
9.7431 1.3764 1.7044 -
0.3280
0.5867 0.1752 -
0.7674
0.7472
22222 
1.6736
11111 
11.201
38889 
1.3890
97222 
11.201
4 
1.3891 1.7109 -
0.3218
0.5845 0.1772 -
0.7527
 
 
Diagnostics 
 
Function Item Value 
1 CSS 10.596 
1 WCSS 13.728 
1 SSR 3.04904 
1 WSSR 2.62737 
1 S 0.353713 
1 DF 21 
1 CORR_(OBS,PRED) 0.844 
1 AIC 26.21762 
1 SBC 28.48861 
 
 
Partial Derivatives 
 
Function Time (mmol/l) N K 
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1 1.14E-02 0.10434956 0.07211385 
1 1.51E-02 0.11957209 0.08162460 
1 3.53E-02 0.17682545 0.11327810 
1 3.58E-02 0.17806129 0.11387645 
1 5.78E-02 0.21900630 0.13124649 
1 7.07E-02 0.23778139 0.13744921 
1 0.108402778 0.28024002 0.14673293 
1 0.137916667 0.30505391 0.14875778 
1 0.193055556 0.33978849 0.14685663 
1 0.301736111 0.38395849 0.13556623 
1 0.423958333 0.41446533 0.12135264 
1 0.429513889 0.41556300 0.12073703 
1 0.447916667 0.41906192 0.11872502 
1 0.682638889 0.45076292 0.09694776 
1 0.695833333 0.45204895 0.09592561 
1 0.850694444 0.46472702 0.08525010 
1 1.470833333 0.49198929 0.05850038 
1 3.326388889 0.51643017 0.02991566 
1 4.211805556 0.52086796 0.02424086 
1 4.395833333 0.52157640 0.02332090 
1 9.694444444 0.53068969 0.01113845 
1 9.743055556 0.53072842 0.01108530 
1 11.20138889 0.53173674 0.00969712 
 
 
X vs. Observed Y and Predicted Y 
 
0.0
0.5
1.0
1.5
2.0
2.5
0 2 4 6 8 10 12
CU (mmol/l)
Observed
Predicted
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Observed Y vs. Weighted Predicted Y 
 
0.2
0.4
0.6
0.8
1.0
1.2
1.4
0.0 0.5 1.0 1.5 2.0 2.5
Dbi-calc
 
 
Weighted Predicted Y vs. Weighted Residual Y 
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-0.0
0.2
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X vs. Weighted Residual Y 
 
-0.6
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NONMEM CODES 
 
$PROB PPB DATA FROM NINE VOLUNTEERS 
$DATA ..\PPB.csv IGNORE # 
$INPUT ID CU CBBE CBAF DBI=DV ALB GEN AGE WT HT BMI PROT 
$PRED  
IF(GEN.EQ.1)  I2 = 1                   ;SET IND. FOR FEMALE 
IF(GEN.EQ.2)  I2 = 0                   ;SET IND. FOR MALE 
N=THETA(1)*EXP(ETA(1))                 ;NUMBER OF BINDING SITES 
K=THETA(2)*EXP(ETA(2))                 ;AFFINITY CONSTANT, WITH 
INTERINDIVIDUAL VARIABILITY  
F=((N*K*CU*ALB)/(1+K*CU))              ;ONE SATURABLE BINDING SITE 
DEL=0 
IF (F.EQ.0) DEL=0.000025; PREVENTS IWRES FROM BLOWING UP FOR F=0 
IPRED=F 
W=IPRED+DEL 
IRES=DV-IPRED 
IWRES=IRES/W 
Y=W*(1+ERR(1)) 
$THETA  
(0, 2)         ; N 
(0, 10)        ; K 
$OMEGA  
0 FIXED 
0.1  
$SIGMA 
0.1 
$EST NOABORT SIG=3 MAX=2000 PRINT=1 METHOD = 1; FOCE METHOD 
$COV 
$SCATTER PRED VS DV UNIT 
$SCATTER IPRED VS DV UNIT 
$SCATTER PRED VS RES  
$SCATTER IPRED VS IWRES UNIT 
$SCATTER WRES VS ALB  
$SCATTER WRES VS GEN 
$SCATTER WRES VS AGE 
$SCATTER PRED VS WRES 
$TABLE ID CU N K ALB AGE GEN WT BMI PROT IPRED IWRES  
ETA(2) FIRSTONLY NOPRINT FILE=base.fit 
$TABLE ID CU N K ALB AGE GEN WT BMI PROT IPRED IWRES  
ETA(2) NOPRINT FILE=PPB.fit 
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$PROB PK DATA FROM NINE VOLUNTEERS 
$DATA ..\PK-9.csv IGNORE # 
$INPUT ID DAY=DROP TIME DV AMT DOSE RATE EVID MDV ALB GEN AGE 
WT HT BMI PROT 
 
$SUBROUTINE  ADVAN6  TOL=3 ; SET UP DIFFERENTIAL EQUATION MODE 
$MODEL COMP(CENTRAL,DEFDOSE) ; JUST ONE COMPARTMENT 
 
$PK ; DEFINE BASIC PK RELATIONSHIPS 
   CL = THETA(1)*EXP(ETA(1))  
   V = THETA(2)*EXP(ETA(2)) 
   D1 =THETA(3)*EXP(ETA(3)) 
    K= CL/V 
 
$DES ; DEFINE DIFFERENTIAL EQUATIONS 
   DADT(1) =  -A(1) * K  
 
$ERROR ; COMPUTE DV FROM STATE VARIABLES 
Y= A(1)/V * (1+EPS(1)) 
;F= A(1)/V  
;DEL=0 
;IF (F.EQ.0) DEL=0.000025;  PREVENTS IWRES FROM BLOWING UP FOR F=0 
;IPRED=F 
;W=IPRED+DEL 
;IRES=DV-IPRED 
;IWRES=IRES/W 
;Y=W*(1+ERR(1))    
 
$THETA (1, 20)             ;CL 
$THETA (2,150)            ;V 
$THETA (0.1,8)           ;DURATION 
;$THETA (1, 12)           ; 
;$THETA (-0.1,0.18,0.55)  ;CL_AGE 
;$THETA (0.6,1,2)         ;CL_SMK 
;$THETA (-0.1,0.01,2)     ;CL_CGLF 
;$THETA (0.25,1,3)        ;F_GEN 
$OMEGA  0.1           ;CL 
$OMEGA  0.2           ;V 
$OMEGA  0 FIX           ;DUR 
;$OMEGA BLOCK (2) 0.1 0.15 0.5 ;CL-V 
$SIGMA 0.15                  ;PROP 
;MSFI= 
$EST NOABORT MAXEVAL=4000 SIGDIGITS=3 PRINT=5 METH=1 INTER 
$COV 
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;$SCATTER PRED VS DV UNIT 
;$SCATTER IPRED VS DV UNIT 
;$SCATTER PRED VS RES  
;$SCATTER IPRED VS IWRES UNIT 
;$SCATTER WRES VS GEN 
;$SCATTER WRES VS AGE 
;$SCATTER PRED VS WRES 
;$TABLE ID DV AGE GEN WT BMI IPRED IWRES FIRSTONLY NOPRINT 
FILE=PK1.FIT 
;$TABLE ID DV AGE GEN WT BMI IPRED IWRES NOPRINT FILE=PK.FIT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NONMEM OUTPUT 
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1NONLINEAR MIXED EFFECTS MODEL PROGRAM (NONMEM)    DOUBLE 
PRECISION NONMEM    VERSION V LEVEL 1.1   
 DEVELOPED AND PROGRAMMED BY STUART BEAL AND LEWIS SHEINER 
  
 PROBLEM NO.:         1 
 PK DATA FROM NINE VOLUNTEERS                                             
0DATA CHECKOUT RUN:              NO  
 DATA SET LOCATED ON UNIT NO.:    2 
 THIS UNIT TO BE REWOUND:        NO  
 NO. OF DATA RECS IN DATA SET:  336 
 NO. OF DATA ITEMS IN DATA SET:  14 
 ID DATA ITEM IS DATA ITEM NO.:   1 
 DEP VARIABLE IS DATA ITEM NO.:   3 
 MDV DATA ITEM IS DATA ITEM NO.:  7 
0INDICES PASSED TO SUBROUTINE PRED: 
  6  2  4  5  0  0  0  0  0 
  0  0 
0LABELS FOR DATA ITEMS: 
   ID    TIME      DV     AMT    RATE    EVID     MDV     ALB     GEN 
  AGE      WT      HT     BMI    PROT 
0FORMAT FOR DATA: 
 (E2.0,2E6.0,E5.0,E3.0,2E2.0,E7.0,E2.0,E3.0,E4.0,2E5.0,E4.0)                      
  
 TOT. NO. OF OBS RECS:     152 
 TOT. NO. OF INDIVIDUALS:    8 
0LENGTH OF THETA:  3 
0OMEGA HAS SIMPLE DIAGONAL FORM WITH DIMENSION:  3 
0SIGMA HAS SIMPLE DIAGONAL FORM WITH DIMENSION:  1 
0INITIAL ESTIMATE OF THETA: 
 LOWER BOUND    INITIAL EST    UPPER BOUND 
  0.1000E+01     0.9000E+01     0.1000E+07 
  0.2000E+01     0.1860E+03     0.1000E+07 
  0.1000E+00     0.1000E+02     0.1000E+07 
0INITIAL ESTIMATE OF OMEGA: 
 0.1000E+00 
 0.0000E+00   0.1000E+00 
 0.0000E+00   0.0000E+00   0.1000E+00 
0INITIAL ESTIMATE OF SIGMA: 
 0.8000E-01 
0ESTIMATION STEP OMITTED:           NO  
 CONDITIONAL ESTIMATES USED:       YES  
 CENTERED ETA:                      NO  
 EPS-ETA INTERACTION:              YES  
 LAPLACIAN OBJ. FUNC.:              NO  
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 NO. OF FUNCT. EVALS. ALLOWED:    4000 
 NO. OF SIG. FIGURES REQUIRED:       3 
 INTERMEDIATE PRINTOUT:            YES  
 ESTIMATE OUTPUT TO MSF:            NO  
 ABORT WITH PRED EXIT CODE 1:       NO  
0COVARIANCE STEP OMITTED:    NO  
 EIGENVLS. PRINTED:    NO  
 SPECIAL COMPUTATION:  NO  
 COMPRESSED FORMAT:    NO  
1DOUBLE PRECISION PREDPP VERSION IV LEVEL 1.1   
  
 GENERAL NONLINEAR KINETICS MODEL (ADVAN6) 
0MODEL SUBROUTINE USER-SUPPLIED - ID NO. 9999 
0MAXIMUM NO. OF BASIC PK PARAMETERS:   1 
0COMPARTMENT ATTRIBUTES  
 COMPT. NO.   FUNCTION   INITIAL    ON/OFF      DOSE      DEFAULT    
DEFAULT 
                         STATUS     ALLOWED    ALLOWED    FOR DOSE   FOR OBS. 
    1         CENTRAL      ON         YES        YES        YES        YES 
    2         OUTPUT       OFF        YES        NO         NO         NO  
0NRD VALUE FROM SUBROUTINE TOL:   3 
1 
 ADDITIONAL PK PARAMETERS - ASSIGNMENT OF ROWS IN GG 
 COMPT. NO.                             INDICES 
              SCALE      BIOAVAIL.   ZERO-ORDER  ZERO-ORDER  ABSORB 
                         FRACTION    RATE        DURATION    LAG   
    1           *           *           *           2           * 
    2           *           -           -           -           - 
             - PARAMETER IS NOT ALLOWED FOR THIS MODEL 
             * PARAMETER IS NOT SUPPLIED BY PK SUBROUTINE; 
               WILL DEFAULT TO ONE IF APPLICABLE 
0DATA ITEM INDICES USED BY PRED ARE: 
   EVENT ID DATA ITEM IS DATA ITEM NO.:      6 
   TIME DATA ITEM IS DATA ITEM NO.:          2 
   DOSE AMOUNT DATA ITEM IS DATA ITEM NO.:   4 
   DOSE RATE DATA ITEM IS DATA ITEM NO.:     5 
  
0PK SUBROUTINE CALLED WITH EVERY EVENT RECORD. 
 PK SUBROUTINE NOT CALLED AT NONEVENT (ADDITIONAL OR LAGGED) 
DOSE TIMES. 
0ERROR SUBROUTINE CALLED WITH EVERY EVENT RECORD. 
0DES SUBROUTINE USES COMPACT STORAGE MODE 
1 
 MONITORING OF SEARCH: 
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0ITERATION NO.:    0     OBJECTIVE VALUE:  0.3568E+03     NO. OF FUNC. 
EVALS.: 6 
 CUMULATIVE NO. OF FUNC. EVALS.:    6 
 PARAMETER:  0.1000E+00  0.1000E+00  0.1000E+00  0.1000E+00  0.1000E+00  
0.1000E+00  0.1000E+00 
 GRADIENT:   0.4468E+03 -0.7039E+03  0.3495E+03 -0.3117E+03  0.3577E+02 -
0.1645E+03  0.4818E+03 
0ITERATION NO.:    5     OBJECTIVE VALUE:  0.3488E+03     NO. OF FUNC. 
EVALS.:20 
 CUMULATIVE NO. OF FUNC. EVALS.:   61 
 PARAMETER:  0.7053E-01  0.1179E+00  0.1037E+00  0.3067E+00  0.2052E+00  
0.2469E+00  0.8598E-01 
 GRADIENT:  -0.4564E+04 -0.4544E+03 -0.5192E+03  0.4704E+02  0.3883E+02  
0.1258E+02  0.8373E+03 
0ITERATION NO.:   10     OBJECTIVE VALUE:  0.3423E+03     NO. OF FUNC. 
EVALS.: 8 
 CUMULATIVE NO. OF FUNC. EVALS.:  123 
 PARAMETER:  0.7053E-01  0.1165E+00  0.1037E+00  0.1276E+00  0.2034E+00  
0.2421E+00  0.8579E-01 
 GRADIENT:   0.1342E+04 -0.4894E+04 -0.5387E+04  0.6220E+02  0.1448E+02  
0.3025E+02 -0.7310E+04 
0ITERATION NO.:   15     OBJECTIVE VALUE:  0.3405E+03     NO. OF FUNC. 
EVALS.:18 
 CUMULATIVE NO. OF FUNC. EVALS.:  192 
 PARAMETER:  0.7052E-01  0.1164E+00  0.1037E+00  0.1059E+00  0.2032E+00  
0.2415E+00  0.8581E-01 
 GRADIENT:  -0.1233E+05 -0.6500E+04 -0.1202E+05  0.4236E+02  0.1406E+02  
0.2611E+02  0.1262E+05 
0ITERATION NO.:   17     OBJECTIVE VALUE:  0.3405E+03     NO. OF FUNC. 
EVALS.:16 
 CUMULATIVE NO. OF FUNC. EVALS.:  227 
 PARAMETER:  0.7052E-01  0.1164E+00  0.1037E+00  0.1058E+00  0.2032E+00  
0.2415E+00  0.8581E-01 
 GRADIENT:  -0.1307E+05 -0.1081E+05 -0.1202E+05 -0.1203E+05  0.3174E+04 -
0.5337E+04  0.1262E+05 
0MINIMIZATION SUCCESSFUL 
 NO. OF FUNCTION EVALUATIONS USED:  227 
 NO. OF SIG. DIGITS IN FINAL EST.:  3.3 
 
 ETABAR IS THE ARITHMETIC MEAN OF THE ETA-ESTIMATES, 
 AND THE P-VALUE IS GIVEN FOR THE NULL HYPOTHESIS THAT THE TRUE 
MEAN IS 0. 
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 ETABAR:   0.83E-01 -0.47E+00 -0.15E+00 
 
 P VAL.:   0.37E+00  0.58E-04  0.37E+00 
1 
  
 *********************************************************************** 
 MINIMUM VALUE OF OBJECTIVE FUNCTION*****************************                  
 **********************       340.479 **************************************     
 
 ********************  FINAL PARAMETER ESTIMATE********************                       
  
  THETA - VECTOR OF FIXED EFFECTS PARAMETERS   ******************** 
 
            TH 1      TH 2      TH 3 
  
         4.98E+00  2.51E+02  1.07E+01 
  
 OMEGA - COV MATRIX FOR RANDOM EFFECTS - ETAS  ******** 
 
            ETA1      ETA2      ETA3 
  
 ETA1 
+        1.12E-01 
  
 ETA2 
+        0.00E+00  4.13E-01 
  
 ETA3 
+        0.00E+00  0.00E+00  5.83E-01 
  
SIGMA - COV MATRIX FOR RANDOM EFFECTS - EPSILONS  **** 
 
 
            EPS1 
  
 EPS1 
+        5.89E-02 
  
******************** STANDARD ERROR OF ESTIMATE*****************                         
 
 
 THETA - VECTOR OF FIXED EFFECTS PARAMETERS   ********* 
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            TH 1      TH 2      TH 3 
  
         6.96E-03  3.67E-01  2.12E-02 
  
 
 
 OMEGA - COV MATRIX FOR RANDOM EFFECTS - ETAS  ******** 
 
 
            ETA1      ETA2      ETA3 
  
 ETA1 
+        4.37E-04 
  
 ETA2 
+       .........  1.46E-03 
  
 ETA3 
+       ......... .........  1.50E-03 
  
 
 
 SIGMA - COV MATRIX FOR RANDOM EFFECTS - EPSILONS  **** 
 
 
            EPS1 
  
 EPS1 
+        1.93E-04 
  
 
 
 
 
 
 
 
********************   COVARIANCE MATRIX OF ESTIMATE ***************                          
 
 
            TH 1      TH 2      TH 3      OM11      OM12      OM13      OM22      OM23      
OM33      SG11 
  
 TH 1 
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+        4.85E-05 
  
 TH 2 
+        2.55E-03  1.35E-01 
  
 TH 3 
+        1.45E-04  7.66E-03  4.50E-04 
  
 OM11 
+        3.02E-06  1.60E-04  9.22E-06  1.91E-07 
  
 OM12 
+       ......... ......... ......... ......... ......... 
  
 OM13 
+       ......... ......... ......... ......... ......... ......... 
  
 OM22 
+       -1.01E-05 -5.32E-04 -3.08E-05 -6.36E-07 ......... .........  2.12E-06 
  
 OM23 
+       ......... ......... ......... ......... ......... ......... ......... ......... 
  
 OM33 
+        1.04E-05  5.51E-04  3.17E-05  6.56E-07 ......... ......... -2.19E-06 .........  2.26E-06 
  
 SG11 
+       -1.32E-06 -6.98E-05 -4.10E-06 -8.40E-08 ......... .........  2.80E-07 ......... -2.89E-07  
3.73E-08 
  
                
 
 
 
 
 
   *****************************CORRELATION MATRIX***************** 
 
 
            TH 1      TH 2      TH 3      OM11      OM12      OM13      OM22      OM23      
OM33      SG11 
  
 TH 1 
+        1.00E+00 
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 TH 2 
+        9.98E-01  1.00E+00 
  
 TH 3 
+        9.82E-01  9.83E-01  1.00E+00 
  
 OM11 
+        9.95E-01  9.96E-01  9.95E-01  1.00E+00 
  
 OM12 
+       ......... ......... ......... ......... ......... 
  
 OM13 
+       ......... ......... ......... ......... ......... ......... 
  
 OM22 
+       -9.94E-01 -9.95E-01 -9.96E-01 -1.00E+00 ......... .........  1.00E+00 
  
 OM23 
+       ......... ......... ......... ......... ......... ......... ......... ......... 
  
 OM33 
+        9.97E-01  9.98E-01  9.93E-01  1.00E+00 ......... ......... -9.99E-01 .........  1.00E+00 
  
 SG11 
+       -9.83E-01 -9.83E-01 -9.99E-01 -9.95E-01 ......... .........  9.97E-01 ......... -9.93E-01  
1.00E+00 
  
 
 
 
 
 
 
********** INVERSE COVARIANCE MATRIX OF ESTIMATE ************             
 
            TH 1      TH 2      TH 3      OM11      OM12      OM13      OM22      OM23      
OM33      SG11 
  
 TH 1 
+        2.27E+08 
  
 TH 2 
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+       -1.15E+07  1.71E+06 
  
 TH 3 
+        9.08E+07  5.95E+06  1.42E+08 
  
 OM11 
+        2.45E+10 -5.08E+09 -2.72E+10  1.60E+13 
  
 OM12 
+       ......... ......... ......... ......... ......... 
  
 OM13 
+       ......... ......... ......... ......... ......... ......... 
  
 OM22 
+        1.20E+10 -8.42E+08  2.84E+09  2.08E+12 ......... .........  7.06E+11 
  
 OM23 
+       ......... ......... ......... ......... ......... ......... ......... ......... 
  
 OM33 
+        5.33E+09  4.96E+07  5.52E+09 -5.82E+11 ......... .........  2.35E+11 .........  
2.45E+11 
  
 SG11 
+        2.65E+09 -1.29E+09 -9.84E+09  4.23E+12 ......... .........  3.50E+11 ......... -
2.89E+11  1.27E+12 
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